Medications used to reduce amyloid formation

By using drugs derived from the N-terminal region of CagA (CagAN), the challenges of amyloid formation and biofilm stability have been addressed, enabling effective treatment of Alzheimer's disease and bacterial infections, as well as restoration of antibiotic sensitivity.

CN123124987APending Publication Date: 2026-11-17陈格飞
View PDF 38 Cites 0 Cited by

Patent Information

Application Number
CN202480090993.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-03-26
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

Existing technologies are insufficient to effectively reduce and prevent the formation of amyloid, especially in Alzheimer's disease and biofilm-related bacterial infections, leading to increased treatment difficulty and antibiotic resistance problems.

Method used

Using the N-terminal region (CagAN) of the CagA protein secreted by Helicobacter pylori, or a portion thereof or a variant thereof, as an agent, it inhibits protein aggregation and biofilm stability by reducing and preventing the formation of amyloid.

Benefits of technology

It significantly reduces the formation of amyloid by 10% to 99% and disrupts the structural integrity of biomembranes, thereby improving therapeutic efficacy and antibiotic sensitivity.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123124987A_ABST
    Figure CN123124987A_ABST
Patent Text Reader

Abstract

This invention relates to the use of pharmaceutical agents for reducing and / or preventing and / or reversing the formation of amyloid substances.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This invention relates to the use of a pharmaceutical agent for reducing and / or preventing and / or reversing amyloid formation, wherein the agent comprises the N-terminal region of CagA (CagA N CagA, or a portion or variant thereof, or composed thereof, wherein the N-terminal region of CagA, or a portion or variant thereof, is capable of reducing and / or preventing and / or reversing amyloid formation; uses and methods for reducing and / or preventing and / or reversing microbial biofilm formation; uses and methods for preventing and / or treating diseases or conditions characterized by amyloid formation; and combinations and compositions comprising the agent.

[0002] Protein aggregation and amyloid formation have historically been associated with a variety of diseases, such as Alzheimer's and Parkinson's. These pathological amyloids are insoluble, fibrous protein aggregates that accumulate abnormally in various tissues and organs, contributing to the pathogenesis of amyloidosis. Unlike normal proteins that fold into specific three-dimensional structures to perform their biological functions, pathological amyloids undergo misfolding and aggregation, forming β-sheet-rich fibrils resistant to degradation. Alzheimer's disease (AD) is the most common type of dementia, causing progressive memory loss and severe cognitive impairment, resulting in a considerable social burden. At the neuropathological level, the brains of AD patients exhibit β-amyloid (Aβ) plaques, neurofibrillary tangles, and neuroinflammation (Sala Frigerio and De Strooper, (2016) Alzheimer's disease mechanisms and emerging roads to novel therapeutics. AnnuRev Neurosci 39:57-79). The increasing number of individuals affected by AD underscores the urgent need to develop effective treatments, and a cure remains elusive.

[0003] Biofilms are microbial communities in which microorganisms live within a matrix of hydrated extracellular polymeric substances (EPS), which forms the biofilm's scaffold. Bacteria form biofilms to retain nutrients and water, adhere to surfaces and other bacterial cells, and also act as a protective barrier. Pathogenic microorganisms associated with biofilms are protected from antimicrobial agents and the host's immune system, making them more infectious and harder to treat. 80% of all chronic infections are related to bacterial biofilms. Aggregates, existing in the form of amyloid fibrils, play a crucial role in maintaining the structural integrity of biofilms; when these proteins mutate, the biofilm is disrupted, exposing bacteria to treatments such as antibiotics.

[0004] Not all amyloids are pathological; some have biological functions in the organisms that produce them, hence the term "functional amyloids." These functional amyloids can strengthen biomembranes, thus posing a significant threat to human health because chronic infections they cause are difficult to treat due to the structural integrity of the biomembrane and insufficient drug penetration, thereby promoting antibiotic resistance. Targeting biomembranes may be a novel approach to combating antibiotic resistance, which causes millions of deaths annually and is estimated to cause more deaths than cancer by 2050. However, structural information about biomembranes and their fibrous components, and how these components interact with other proteins, is very limited.

[0005] Against this backdrop, the inventors surprisingly discovered that a portion of the CagA (cytotoxin-associated gene A) protein secreted by Helicobacter pylori has broad-spectrum anti-amyloid activity, thus providing a new approach to combating bacterial infections and / or human protein misfolding diseases.

[0006] In one aspect, the present invention provides the use of an agent for reducing and / or preventing and / or reversing amyloid formation, wherein the agent comprises the N-terminal region of CagA (CagA N CagA, or a portion or variant thereof, or composed thereof, has an N-terminal region or a portion or variant thereof capable of reducing and / or preventing and / or reversing amyloid formation.

[0007] In one aspect, the present invention provides a method for reducing and / or preventing and / or reversing amyloid formation in a subject, the method comprising administering to the subject an effective amount of an N-terminal region containing CagA (CagA N CagA, or a portion or variant thereof, or an agent comprising thereof, wherein the N-terminal region of CagA, or a portion or variant thereof, is capable of reducing and / or preventing and / or reversing the formation of amyloid fibrils.

[0008] In one aspect, the present invention provides a method for reducing and / or preventing and / or reversing the formation of amyloid material on a non-living surface, the method comprising reacting the amyloid material with an N-terminal region containing CagA (CagA N Contact with agents containing or consisting of CagA, or a portion thereof or a variant thereof, or a component thereof, enables the N-terminal region of CagA, or a portion thereof or a variant thereof, to reduce and / or prevent and / or reverse amyloid fibrillation. Examples of surfaces are described herein. “Non-living surface” includes the meaning of a surface outside of a human or animal body.

[0009] The basic structural component of amyloid is the protofibril. Amyloid protofibrils are composed of twisted protofilaments. Amyloid protofibrils can be formed from one, two, three, four, or many of these protofilaments. The protofilaments are linked to each other in a parallel manner through their side chains. "Amyloid formation" involves the misfolding and aggregation of certain proteins to form insoluble fibrous structures, typically characterized by cross-beta-sheet structures known as amyloid protofibrils. These protofibrils exhibit a characteristic protofibrillary superstructure, X-ray crystallography, and binding to dyes such as thioflavone T and Congo red. Typical birefringence is also visible after staining with the latter dye. These protofibrils can deposit extracellularly and accumulate in various tissues and organs, leading to tissue damage and dysfunction. Amyloid protofibrils are associated with several neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease, as well as other conditions such as type 2 diabetes. We also include "functional" or non-pathological amyloid formation from amyloid protofibrils. In nature, beta-sheet protofibrils serve many functions. Some polypeptide hormones are stored in a β-sheet conformation, perhaps not in the form of regular fibrils; melanin binds to β-sheet fibrous carriers (p-mel17) within melanosomes. Several bacterial and fungal organisms utilize the strength of β-sheet fibrils. Bacteria produce several different structures, such as biofilms, which have a β-sheet fibrous composition. The presence of amyloid fibrils in the biofilm matrix can protect microbial cells from environmental stresses, including antimicrobial agents, host immune responses, and fluctuations in nutrient availability. The fungus *Neurospora crassa* expresses the hydrophobic protein EAS, which forms an amphiphilic amyloid monolayer, promoting spore formation and dispersal. These are examples of functional amyloid substances.

[0010] "Reducing and / or preventing and / or reversing amyloid formation" includes the following meanings: inhibiting protein aggregation into amyloid fibrils, or destabilizing existing fibrils, thereby reducing or preventing the progression of diseases associated with amyloid deposits, and / or reducing or preventing biofilm formation. For example, in subjects receiving the medication described herein, the amount of amyloid formation will be reduced and / or prevented and / or reversed compared to the amount of amyloid formation in subjects who did not receive the medication. For example, amyloid formation in subjects receiving the agent described herein may be reduced by 10%, 20%, 30%, or 40% compared to amyloid formation in subjects who did not receive the agent, such as at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%. In one embodiment, the use for reducing and / or preventing and / or reversing amyloid formation is performed in vitro in humans or animals.

[0011] Measuring amyloid formation in patients typically involves a combination of clinical assessment, imaging techniques, and laboratory tests. Common methods for detecting and quantifying amyloid deposits include clinical assessment by a healthcare provider, which may involve evaluating symptoms and signs suggestive of amyloid-related diseases, such as cognitive decline in Alzheimer's disease or cardiac involvement in systemic amyloidosis. Imaging techniques, such as positron emission tomography (PET), which uses radioactive tracers (such as Pittsburgh compound B (PiB) or flubetapyr), are used to visualize amyloid deposits in the brains of patients suspected of having Alzheimer's disease. Cardiac magnetic resonance imaging (MRI) with gadolinium delayed enhancement (LGE) can detect myocardial amyloid deposits in patients with cardiac amyloidosis. Scintillation scanning using radioactive tracers (such as technetium-99m-labeled bisphosphonates) can detect amyloid deposits in the bone marrow of patients with systemic amyloidosis. Tissue biopsies (such as those taken from the skin, gastrointestinal tract, or affected organs), followed by histopathological examination and staining techniques (e.g., polarized light), are also used. The presence of amyloid deposits can be confirmed by staining with Congo red (which shows apple green birefringence), and the specific type of amyloid protein can be identified. Serum and urine protein electrophoresis can detect abnormal protein bands suggestive of monoclonal gammopathy, which may be associated with systemic amyloidosis. Immunohistochemical staining of tissue samples can identify the specific amyloid proteins involved, such as β-amyloid in Alzheimer's disease or immunoglobulin light chains in systemic amyloidosis. Blood or cerebrospinal fluid biomarker assays (such as measurements of β-amyloid 42 (Aβ42) and tau protein) can be used in a research setting to assess amyloid burden and neuronal damage in Alzheimer's disease.

[0012] As used herein, "effective amount" means an amount sufficient to achieve the desired effect. In the context of therapeutic or preventative application, the effective amount will depend on the type and severity of the condition in question and the characteristics of the individual subject, such as general health status, age, sex, weight, and tolerance to the pharmaceutical composition. Those skilled in the art will be able to determine the appropriate amount based on these and other factors. In the case of in vitro application, in some embodiments, the effective amount will depend on the size and nature of the application in question. It will also depend on the nature and sensitivity of the in vitro target and the method used. Those skilled in the art will be able to determine the effective amount based on these and other considerations. Depending on the embodiment, the effective amount may include a single or multiple administrations of the composition.

[0013] As used herein, “CagA” includes the meaning of the CagA protein, a virulence factor secreted by Helicobacter pylori. An exemplary full-length CagA protein from Helicobacter pylori has the characteristics shown in SEQ ID NO: 1 ( Figure 1The amino acids shown in b) are 1-1186. These numbers correspond to CagA from Helicobacter pylori strain 26695 (Tomb JF, et al., Nature. 1997; 388:539–547). CagA consists of multiple domains / regions: an N-terminal structured region and a disordered C-terminal tail for interfering with host signal transduction. Figure 1 a and Figure 1 b) (Hatakeyama, M. Proc. Jpn. Acad. Ser. B Phys. Biol. Sci. 93, 196-219 (2017); and Kaplan-Türköz, B. et al., Proc. Natl. Acad. Sci. USA 109, 14640-14645 (2012)).

[0014] In one embodiment, CagA comprises, or consists of, the sequence of amino acids 1-1186 of Helicobacter pylori strain 26695 or its orthologs, optionally wherein CagA has the amino acid sequence of SEQ ID NO: 1. In one embodiment, CagA has the amino acid sequence of SEQ ID NO: 1. In one embodiment, CagA has the sequence of amino acids 1-1186 of Helicobacter pylori strain 26695, or its orthologs, such as those from Helicobacter pylori strains G27 (Bagnoli F. et al., (2005) Proc.Natl.Acad.Sci. USA 102, 16339–16344), V225 (Olbermann P, et al., PLoS Genet. 2010; 6:e1001069), HP-No20, and HP-No31 (Truong BX, et al., J ClinMicrobiol. 2009; 47:4021–4028). "Ortholog" includes genes found in different species that share a common evolutionary origin. Those skilled in the art can determine whether a sequence is CagA or CagA from Helicobacter pylori strain 26695 using methods known in the art. NOrthologs can be identified by various computational and experimental methods, including determining sequence similarity, as orthologs typically exhibit high sequence similarity across species. Computational tools, such as BLAST (Basic Local Alignment Search), can be used to search for homologous sequences between different species. Phylogenetic analysis can be used, thus, by constructing phylogenetic trees based on gene sequences from different species, those skilled in the art can identify orthologs by observing patterns of gene divergence and speciation events. Collinearity analysis can be used, as orthologs typically reside in similar genomic backgrounds (collinearity) across different species, and comparing the genomic organization of genes in different species can aid in the identification of orthologs. Functional analysis can be used, as orthologs tend to perform similar functions across different species; therefore, experimental studies, such as gene knockout experiments or functional assays, can be used to verify the functional conservation of orthologs.

[0015] In one embodiment, the agent comprises the N-terminal region of CagA (CagA N In one embodiment, the agent is composed of the N-terminal region of CagA (CagA...). N The term "N-terminal region of CagA" refers to the N-terminal region spanning positions 1 to 884 of CagA. N Due to structural polymorphism in the C-terminal region, the size of CagA protein ranges from 130 kDa to 145 kDa (Hatakeyama, M. Proc. Jpn. Acad. Ser. B Phys. Biol. Sci. 93, 196-219 (2017)).

[0016] In one embodiment, the agent comprises the N-terminal region of CagA (CagA N ( ) is part of or composed of. "The N-terminal region of CagA (CagA N The "part" of "(CagA)" includes CagA N The term "CagA" refers to the segment or fragment of a protein's primary structure, which is the linear sequence of amino acids that make up the protein chain. Protein segments can vary in size and range from short amino acid sequences (such as peptides or domains) to larger segments encompassing multiple domains or functional regions within the protein. N A specific component must be able to reduce and / or prevent and / or reverse amyloid formation.

[0017] In one embodiment, the agent comprises the N-terminal region of CagA (CagA N Variants of or composed of CagA. The N-terminal region of CagA (CagA NVariants of CagA include those derived from CagA. N The meaning of a polypeptide is that the polypeptide contains alterations, namely substitutions, insertions, and / or deletions, at one or more positions, which maintain the ability to reduce and / or prevent and / or reverse amyloid formation (i.e., functional equivalence). It should be understood that CagA... N Functional equivalents or variants are also within the scope of this invention, such as those variants with conserved amino acid substitutions. A conserved substitution is generally the replacement of one amino acid by another amino acid belonging to the same class. For example, it is well known in the field of protein biochemistry that amino acids belonging to a group of amino acids with specific sizes or characteristics (such as charge, hydrophobicity, and / or hydrophilicity) can often be replaced by another amino acid without substantially altering the secondary and / or tertiary structure of the polypeptide. For the purposes of this invention, conserved amino acid substitution is defined as resulting from the exchange of amino acid residues within one of the following classes: Class I: Gly, Ala, Val, Leu, and Ile (representing aliphatic side chains); Class II: Gly, Ala, Val, Leu, Ile, Ser, and Thr (representing aliphatic and aliphatic hydroxyl side chains); Class III: Tyr, Ser, and Thr (representing hydroxyl side chains); Class IV: Cys and Met (representing sulfur-containing side chains); Class V: Glu, Asp, Asn, and Gln (side chains containing carboxyl or amide groups); Class VI: His, Arg, and Lys (representing basic side chains); Class VII: Gly, Ala, Pro, Trp, Tyr, Ile, Val, Leu, Phe, and Met (representing hydrophobic side chains); Class VIII: Phe, Trp, and Tyr (representing aromatic side chains); Class IX: Asn and Gln (representing amide side chains). These categories are not limited to naturally occurring amino acids, but also include artificial amino acids, such as β or γ amino acids and those containing non-natural side chains, and / or other similar monomers, such as hydroxy acids. For example, the amino acid sequence of a variant may have CagA N or a portion thereof, wherein CagA N One or more amino acids of the variant polypeptide sequence are altered. The variant polypeptide sequence is preferably a sequence not found in nature.

[0018] Methods for preparing protein variants are well known in the art, including genetic engineering approaches such as introducing mutations into genes encoding target proteins using techniques like site-directed mutagenesis or random mutagenesis. Site-directed mutagenesis allows precise control over the location and nature of amino acid substitutions, insertions, or deletions introduced into the protein sequence. Random mutagenesis techniques (such as error-prone PCR or chemical mutagenesis) produce libraries of mutant proteins with a variety of amino acid alterations, which can be screened for desired functions. Protein variants with desired properties can be designed and engineered using rational design or directed evolution methods. Rational design involves evidence-based alterations to protein sequences based on structural and functional knowledge. Directed evolution methods (such as phage display or yeast surface display) involve generating libraries of protein variants and selecting variants with desired properties through iterative rounds of screening or selection.

[0019] CagA can be tested using the methods described herein (such as thioflavin T (ThT) fluorescence assay). N Variants and the ability to reduce and / or prevent and / or reverse amyloid formation.

[0020] In one implementation, the N-terminal region of CagA (CagA N It contains amino acids 1-884 or their orthologs from CagA of strain 26695, or is composed of them, optionally wherein CagA N Contains, or is composed of, the amino acid sequence of SEQ ID NO: 2. Therefore, in one embodiment, CagA N The portion or variant is a portion or variant of amino acids 1-884 of CagA from strain 26695, optionally CagA N The portion or variant thereof is a portion or variant of the amino acid sequence of SEQ ID NO: 2. SEQ ID NO: 2 is shown in the sequence listing herein. The inventors surprisingly discovered that across the N-terminal region of CagA, referred to herein as "CagA..." N It has effective anti-amyloid activity.

[0021] In one implementation, the N-terminal region of CagA (CagA) is capable of reducing and / or preventing and / or reversing amyloid formation. N The length of some or variants of ) is 20 to 400 amino acids.

[0022] In one embodiment, the portion or variant of the N-terminal region of CagA capable of reducing and / or preventing and / or reversing amyloid formation has a length of 20 to 400 amino acids, such as 20 to 350, 20 to 300, 20 to 250, 20 to 200, 20 to 150, 20 to 100, or 20 to 50 amino acids. In one embodiment, the portion or variant of the N-terminal region of CagA capable of reducing and / or preventing and / or reversing amyloid formation has a length of 100 to 400 amino acids, such as 100 to 350, 100 to 300, 100 to 250, 100 to 200, or 100 to 150 amino acids. In one embodiment, the portion or variant of the N-terminal region of CagA capable of reducing and / or preventing and / or reversing amyloid formation has a length of 200 to 400 amino acids, such as 200 to 350, 200 to 300, or 200 to 250 amino acids. In one embodiment, the portion or variant of the N-terminal region of CagA capable of reducing and / or preventing and / or reversing amyloid formation has a length of 250 to 400 amino acids, such as 250 to 350 amino acids or 250 to 300 amino acids. In one embodiment, the portion or variant of the N-terminal region of CagA capable of reducing and / or preventing and / or reversing amyloid formation has a length of 300 to 400 amino acids, such as 300 to 350 amino acids. In one embodiment, the portion or variant of the N-terminal region of CagA capable of reducing and / or preventing and / or reversing amyloid formation has a length of 350 to 400 amino acids.

[0023] In one embodiment, the N-terminal region of CagA capable of reducing and / or preventing and / or reversing amyloid formation has a length of at least 50 amino acids, such as at least 60, 70, 90, 110, 130, 150, 170, 190, 210, 230, 250, 270, 290, 310, 330, 350, 370, 390, 410, 430, 450, 470, 490, 510, 530, 550, 570, 590, 610, 630, 650, 670, 690, 710, 730, 750, 770, 790, 810, 830, 850, 870, or at least 880 amino acids. In one embodiment, the N-terminal region of CagA, or a variant thereof, capable of reducing and / or preventing and / or reversing amyloid formation, is at least 300 amino acids in length.

[0024] CagA NIt can be divided into domain I (D1), domain II (D2) (SEQ ID NO: 3), and domain III (D3). Domain I contains 10 α-helices; domain II (D2) forms the central core of CagA, spanning residues 300-644 of Helicobacter pylori CagA (SEQ ID NO: 1), and has a large antiparallel β-sheet, containing a subdomain with five α-helices and two short β-sheets; domain III adopts a four-helix bundle structure, and its C-terminal region originates from a long α-helix connecting domains II and III. Figure 1 b). As can be seen in the appended embodiments, the inventors have surprisingly discovered that domain II (D2) is an effective inhibitor of amyloid fibrillation. In one embodiment, the N-terminal region of CagA (CagA N The part containing CagA N Domain II (D2). In one implementation, the N-terminal region of CagA (CagA N The part is from CagA N It consists of domain II (D2).

[0025] In one embodiment, the variant has at least 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with the amino acid sequence of SEQ ID NO: 2, and maintains CagA N At least one of its main properties or similar tertiary structures.

[0026] "Sequence identity" of a polypeptide or protein with another sequence at a certain percentage (e.g., 80%, 85%, 90%, or 95%) means that, when the two sequences are compared, that percentage of amino acids are identical. For the purposes of this invention, sequence identity between two amino acid sequences can be determined using the Needleman-Wunsch algorithm (Needleman & Wunsch, 1970, J Mol Biol 48(3):443-453), which is implemented in the Needle program of the EMBOSS software package (EMBOSS: The European Molecular Biology Open Software Suite, Rice et al., 2000, Trends Genet 16(6):276-277), preferably version 5.0.0 or higher. For example, CagA N The D2 structural domain and CagA N It has 39% sequence identity.

[0027] The terms “protein,” “peptide,” and “polypeptide” are used interchangeably and, in their broadest sense, include compounds containing two or more amino acid subunits, amino acid analogs, or peptide mimics. Subunits may be linked by peptide bonds. In another embodiment, subunits may be linked by other bonds, such as ester bonds, ether bonds, etc. Proteins or peptides must contain at least two amino acids, and there is no limit to the maximum number of amino acids that can constitute a protein or peptide sequence. As used herein, the term “amino acid” refers to natural and / or non-natural amino acids or synthetic amino acids, including glycine and both its D- and L-optical isomers, amino acid analogs, and peptide mimics.

[0028] In one embodiment, the portion comprises SEQ ID NO: 3. In another embodiment, the portion consists of a polypeptide having the sequence SEQ ID NO: 3.

[0029] In one embodiment, the pharmaceutical agent comprises SEQ ID NO: 2. In another embodiment, the pharmaceutical agent consists of a polypeptide having the sequence of SEQ ID NO: 2.

[0030] In amyloid studies, "nucleation (primary)" refers to a concentration-dependent, random event in which misfolded proteins bind together, altering the equilibrium and allowing the attraction of other structurally identical / related molecules. This forms a protofilament that grows by adding new, identical molecules to the ends of the fibrils. This process provides a template for the identical misfolding of subunits. The resulting fibrils do not necessarily exhibit the exact same misfolding as the parent fibrils (Merrill D. Benson, et al., (2020) Amyloid nomenclature 2020: update and recommendations by the International Society of Amyloidosis (ISA) nomenclature committee, Amyloid, 27:4, 217-222). In one embodiment, the agent inhibits fibril formation by blocking primary nucleation, secondary nucleation, and elongation processes, thereby reducing and / or preventing and / or reversing amyloid formation. The kinetics of amyloid aggregation involve different stages, as described in the following reference: Meisl, G., et al., Kinetic Analysis of Amyloid Formation. Methods Mol. Biol. 1779, 181-196 (2018)). Specifically, in the primary nucleation stage, monomers aggregate together to form nuclei (primary nucleation, k...). n The fibrils can begin to extend from here (extension, k) + Simultaneously, during secondary nucleation (k2), monomers adhere to the surface of the protofibrils, catalyzing the formation of new nuclei and promoting exponential growth of the protofibrils (see...). Figure 5 (a) and Figure 5 (b) is a schematic diagram that visually depicts the process. As can be seen from the appended embodiments, the inventors were surprised to find that CagA N It can hinder primary nucleation, secondary nucleation, and elongation processes.

[0031] In one implementation, the N-terminal region of CagA (CagA N The protein, or a portion thereof or a variant thereof, is fused with another protein having anti-amyloid activity, such as the BRICHOS domain. In one embodiment, the protein having anti-amyloid activity is the BRICHOS domain (or a mutant thereof), such as those in SEQ ID NO: 4 or 5.

[0032] BRICHOS is a domain of approximately 100 residues found in 10 human protein families, named after three of them: Bri2 (associated with dementia and brain amyloid), chondroregulatory protein (chondrosarcoma), and surfactant protein C (proSP-C; interstitial lung disease and amyloid). All BRICHOS-containing precursor proteins have highly conserved regions that readily form β-chains. It has been proposed that BRICHOS can assist in the correct folding of amyloid-forming regions in their respective precursor proteins during biosynthesis (Chen et al., Nature Communications volume 8, Article number: 2081 (2017)). Bri2 BRICHOS domains (SEQ ID NO: 4) can cross the blood-brain barrier at a rate of 0.5% to 1% after intravenous injection (Blood-brain and blood-cerebrospinal fluid passage of BRICHOS domains from two molecular chaperones in mice, J Biol Chem. 2019 Feb22;294(8):2606-2615).

[0033] In one embodiment, the ability of the agent to reduce and / or prevent and / or reverse amyloid formation is determined using a thioflavin T (ThT) fluorescence assay, optionally using the ThT assay as described in the appended examples.

[0034] Thioflavin T (ThT) is a benzothiazole dye that exhibits enhanced fluorescence upon binding to amyloid fibrils and is commonly used for the in vitro and in vitro diagnosis of amyloid fibrils. It binds to amyloid structures, resulting in increased fluorescence intensity (see Khurana, R. et al., Mechanism of thioflavin T binding to amyloidfibrils. J. Struct. Biol. 151, 229-238 (2005)). ThT assays are well known in the art and are described in detail in the appended examples. Aggregation kinetics as a function of time can be monitored at a range of different initial monomer concentrations.

[0035] When the agent inhibits amyloid formation, the aggregation kinetics (Y = ThT fluorescence and amyloid fibril mass; X = time) shift to the right, indicating that the amyloid substrate will require more time (in hours) to form amyloid, i.e., inhibition. Alternatively, if the agent is inactive or promotes amyloid formation, the amyloid substrate kinetics will remain unchanged or shift to the left, indicating that in the presence of the agent, the amyloid substrate will form amyloid fibrils normally or require less time to form amyloid (i.e., promotion). ThT measurements are expressed in terms of half-time (τ). 1 / 2 This indicates the time required to reach half of the plateau phase of amyloid formation.

[0036] In one embodiment, the amyloid material is formed from amyloid fibrils and / or amyloid inclusion bodies.

[0037] “Amyloid fibrils” encompasses elongated, insoluble protein aggregates typically characterized by a cross-beta-sheet secondary structure. Amyloid fibrils can appear in tissue deposits as rigid, unbranched fibrils approximately 10 nm in diameter. When stained deposits are observed with a polarizing microscope, the fibrils bind to Congo red dye and exhibit green, yellow, or orange birefringence. When isolated from tissue and analyzed by X-ray diffraction, the fibrils exhibit a characteristic cross-beta diffraction pattern. For chemical identification of amyloid fibrils, immunohistochemistry, Western blotting, mass spectrometry (with or without laser capture), amino acid sequencing, and immunoelectron microscopy are all useful techniques (see, for example, Table 1 and Joel N. Buxbaum et al., (2022) Amyloid nomenclature 2022:update, novel proteins, and recommendations by the International Society of Amyloidosis (ISA) Nomenclature Committee, Amyloid, 29:4, 213-219). According to the Nomenclature Committee of the International Society for Amyloid Degeneration (ISA), the following different categories of amyloid fibrils exist, and those skilled in the art will know of them:

[0038] i. Disease-related fibrils in vivo and in vitro;

[0039] ii. Functional fibrils in vivo and in vitro;

[0040] iii. Recombinant fibrils of disease-associated proteins and functional amyloid proteins;

[0041] iv. Fibrous fibers containing synthetic or non-disease-related peptides; and

[0042] v. Profilaments derived from condensates and hydrogels, which give cross-beta diffraction patterns.

[0043] In this paper, the term “amyloid fibrillary protein” encompasses all members of the amyloid fibrillary class (Joel N. Buxbaum, et al., (2022) Amyloid nomenclature 2022: update, novel proteins, and recommendations by the International Society of Amyloidosis (ISA) Nomenclature Committee, Amyloid, 29:4, 213-219).

[0044] "Amyloid fibrils" also include amyloid fibrils such as p53. P53 is a tumor suppressor protein that is frequently mutated in various malignancies, leading to loss of function. P53 can aggregate into fibrils, and its aggregation pattern resembles that of other amyloid substances. Therefore, it is considered an amyloid fibril protein. However, the characteristic β-sheet structure does not appear to be observed in p53 fibrils in vivo. Fibrous fragments of prostatic acid phosphatase (PAP) are known as seminal fluid-derived viral infection enhancer (SEVI). PAP fragments are thought to play an active role in human immunodeficiency virus infection and have been shown to form in vivo. Therefore, amyloid fibrils may not have a characteristic β-sheet structure, but they can still aggregate into fibrils, and their aggregation pattern resembles that of other amyloid substances.

[0045] We also include functional amyloid fibrils that form nonpathological amyloids. In nature, β-sheet fibrils serve many functions. Some polypeptide hormones are stored in a β-sheet conformation, perhaps not in the form of regular fibrils; melanin binds to β-sheet fibrous carriers (p-mel17) in melanosomes. Several bacterial and fungal organisms utilize the strength of β-sheet fibrils. Bacteria produce several different structures, such as biofilms, which have a β-sheet fibrous composition. The fungus *Neurospora crassa* expresses the hydrophobic protein EAS, which forms an amphiphilic amyloid monolayer, promoting spore formation and dispersal. These are examples of functional amyloids (Joel N. Buxbaum, et al., (2022) *Amyloidnomenclature 2022: update, novel proteins, and recommendations by the International Society of Amyloidosis (ISA) Nomenclature Committee, *Amyloid*, 29:4, 213-219).

[0046] We also include intracellular protein inclusion bodies (such as neurofibrillary tangles), which are described as having a fibrous structure, a cross-beta-sheet X-ray diffraction pattern, and exhibiting green birefringence by binding Congo red.

[0047] "Amyloid inclusion bodies" encompasses intracellular protein inclusion bodies (such as neurofibrillary tangles) that exhibit fibrous structures, cross-beta-sheet X-ray diffraction patterns, and bind to Congo red, displaying green birefringence. Lewy bodies in the brains of Parkinson's disease patients with dementia are composed of fine amyloid fibrils that can sometimes be stained with Congo red and display birefringence (see, for example, Table 2 and Joel N. Buxbaum et al., (2022) Amyloidnomenclature 2022: update, novel proteins, and recommendations by the International Society of Amyloidosis (ISA) Nomenclature Committee, Amyloid, 29:4, 213-219).

[0048] In one embodiment, the amyloid material is formed from amyloid fibrils and / or amyloid inclusion bodies; preferably selected from those listed in Tables 1 and 2.

[0049]

[0050]

[0051] Table 1: Amyloid fibrillin and its precursors in humans. a When possible, proteins are listed according to their relationships. Therefore, apolipoproteins are grouped together, and polypeptide hormones are grouped together as well. b ADan is the same gene product as ABri. c Also known as amylin. (Joel N. Buxbaum et al., (2022) Amyloid nomenclature 2022: update, novel proteins, and recommendations by the International Society of Amyloidosis (ISA) Nomenclature Committee, Amyloid, 29:4, 213-219)

[0052]

[0053] Table 2. Intracellular inclusion bodies with known biochemical composition. a Simplified – other components may exist. b Also included in Table 1, because deposits may appear outside the cells. c ALS: Amyotrophic Lateral Sclerosis; FTD: Frontotemporal Dementia.

[0054] In one implementation, the amyloid material is formed from various mammalian amyloid fibrillary proteins, such as human amyloid fibrillary protein.

[0055] In one embodiment, the amyloid material is formed from a variety of microbial amyloid fibrillary proteins selected from the group consisting of: curli protein; CsgA protein; FapC protein, TasA protein, biofilm-associated protein (Bap); PSM; SuhB; CdrA; CsgA; P1; WapA; SMU_63C; microbesin E492; RbmA; TasA; MTP; Tu elongation factor; HpaG; BE-AM1; Rodlins; Chaplins; Het-s; HET-s-like protein; Sup35; Ure2; HIV-1 Tat protein; hepatitis C virus (HCV) core protein; influenza A virus (IAV) matrix protein M1; and polyomavirus capsid protein.

[0056] Curli proteins (CsgA and CsgB) are major components of extracellular amyloid fibrils produced by several Gram-negative bacteria, including *Escherichia coli* and *Salmonella enterica*. The major curli subunit, CsgA, forms amyloid fibrils, while CsgB acts as a nucleating factor for CsgA polymerization. Curli filaments are involved in biofilm formation and surface adhesion.

[0057] Biofilm-associated protein (Bap) is produced by Staphylococcus aureus and some other bacteria. Bap forms amyloid fibrils, promotes biofilm formation and surface adhesion, and enhances bacterial colonization and persistence.

[0058] TasA is a protein produced by Bacillus subtilis, forming amyloid protofibrils called TasA filaments. These protofibrils participate in the formation and stability of biofilms produced by Bacillus subtilis, promoting surface adhesion and community development.

[0059] Pseudomonas aeruginosa produces amyloid protofibrils composed of FapC protein, which promotes biofilm formation and persistence in chronic infections. FapC amyloid is associated with the development of antibiotic resistance and immune evasion within Pseudomonas aeruginosa biofilms.

[0060] Het-s is a protein from the filamentous fungus *Podospora anserina*, whose formation involves amyloid fibrils in a programmed cell death process called heterokaryotic incompatibility. HET-s-like proteins are similar to Het-s and are found in other fungi, also playing a role in programmed cell death and fungal self-recognition. Sup35 (prion domain) is a protein found in *Saccharomyces cerevisiae*. Its prion domain can switch between soluble and amyloid forms, leading to the formation of [PSI+]prions, which alter the yeast phenotype. Ure2 (prion domain) is another yeast protein from *Saccharomyces cerevisiae*. Its prion domain can also switch between soluble and amyloid forms, leading to the formation of [URE3]prions, which alter nitrogen catabolism repression.

[0061] It has been reported that the transcriptional transactivator (Tat) protein from human immunodeficiency virus type 1 (HIV-1) can form amyloid fibrils in vitro. These fibrils are structurally and functionally similar to amyloid fibrils associated with neurodegenerative diseases. Studies suggest that the core protein of hepatitis C virus (HCV) can aggregate into amyloid fibrils under certain conditions. These aggregates may contribute to the liver pathogenesis in chronic HCV infection. The matrix protein M1 of influenza A virus (IAV) has been shown to form amyloid fibrils in vitro. These fibrils may play a role in viral assembly and budding. Some studies have shown that capsid proteins from certain polyomaviruses (such as JC virus (JCV) and BK virus (BKV)) can form amyloid fibrils under certain conditions. These fibrils may promote viral persistence and pathogenesis in infected individuals.

[0062] In one embodiment, the various microbial amyloid fibrillogenic proteins are various bacterial, fungal, or viral amyloid-forming proteins. In another embodiment, the various microbial amyloid-forming proteins are various bacterial amyloid fibrillogenic proteins.

[0063] In the in vitro studies described herein, doses from nanomolar to micromolar levels were sufficient to prevent / reduce / reverse biofilm formation. The concentration range of the administered drug can vary widely depending on factors such as the route of administration, the patient's age, weight, medical condition, and desired therapeutic effect. For oral administration, concentrations are typically from micrograms / mL to milligrams / mL (μg / mL to mg / mL). For example, a common concentration for liquid oral medications can be 5 mg / mL. For intravenous (IV) administration, concentrations can range from very low concentrations, such as those used for continuous infusion (e.g., 1 μg / mL to 10 μg / mL for some drugs), to higher concentrations used for bolus doses (e.g., 1 mg / mL to 20 mg / mL). Intravenous drugs are typically delivered at standardized concentrations or diluted to achieve the desired dose. For topical administration (including application to surfaces), concentrations vary widely depending on the intended use and the specific formulation. For example, the concentration of the active ingredient in a topical formulation may be from 0.01% to 0.5% (weight / volume), such as 10 mg / mL to 50 mg / mL. For subcutaneous or intramuscular injection, the concentration range can be from micrograms / mL to milligrams / mL (μg / mL to mg / mL), similar to intravenous administration. However, the concentration can be adjusted based on factors such as injection volume and desired absorption rate. These are only general ranges, and the specific concentration should always be determined by a healthcare professional based on the individual patient's needs.

[0064] In one aspect, the present invention provides the use of an agent for reducing and / or preventing and / or reversing microbial biofilm formation, wherein the agent comprises the N-terminal region of CagA (CagA NCagA, or a portion or variant thereof, or composed thereof, has an N-terminal region or a portion or variant thereof capable of reducing and / or preventing and / or reversing amyloid formation.

[0065] In one aspect, the present invention provides the use of an agent for reducing and / or preventing and / or reversing microbial biofilm formation, wherein the agent comprises the N-terminal region of CagA (CagA N CagA, or a portion or variant thereof, or composed thereof, has an N-terminal region or a portion or variant thereof capable of reducing and / or preventing and / or reversing amyloid formation.

[0066] In one aspect, the present invention provides a method for reducing and / or preventing and / or reversing microbial biofilm formation, the method comprising subjecting a biofilm or a surface prone to biofilm formation to an N-terminal region containing CagA (CagA N The steps of contacting the N-terminal region of CagA or a portion or variant thereof or a drug thereof, wherein the N-terminal region of CagA or a portion or variant thereof is capable of reducing and / or preventing and / or reversing amyloid formation.

[0067] In one implementation, the above uses and methods are performed in vitro in humans or animals.

[0068] In one aspect, the present invention provides a method for reducing and / or preventing and / or reversing microbial biofilm formation in a subject, the method comprising administering to the subject an N-terminal region containing CagA (CagA N The steps of a drug comprising or derived from CagA, or a portion thereof or a variant thereof, wherein the N-terminal region of CagA or a portion thereof or a variant thereof is capable of reducing and / or preventing and / or reversing amyloid formation.

[0069] In one aspect, the present invention provides an N-terminal region comprising CagA (CagA N CagA, or a portion thereof or a variant thereof, or an agent comprising thereof, wherein the N-terminal region thereof or a portion thereof or a variant thereof is capable of reducing and / or preventing and / or reversing amyloid formation, for reducing and / or preventing and / or reversing microbial biofilm formation in subjects.

[0070] "Reducing and / or preventing and / or reversing microbial biofilm formation" includes the meaning of reducing the formation of amyloid fibrils, which are components of microbial biofilms. For example, biofilm formation will be reduced and / or prevented and / or reversed upon contact with the agent described herein compared to biofilm formation in the absence of the agent. For example, biofilm formation on a surface contacted with the agent described herein may be reduced and / or prevented and / or reversed by 10%, 20%, 30%, or 40%, such as at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%.

[0071] "Surfaces that are likely to be conducive to microbial biofilm formation" refers to surfaces outside the human or animal body that provide favorable conditions for microbial adhesion and biofilm formation, but which have not yet formed a biofilm. Microorganisms tend to adhere more readily to surfaces with irregularities or roughness because these surfaces offer more opportunities for attachment. Surfaces containing organic or inorganic nutrients can support microbial growth and biofilm formation. For example, surfaces in contact with water, food residue, bodily fluids, or organic matter are generally conducive to biofilm formation. Moist surfaces provide an environment favorable for microbial growth and biofilm formation. Surfaces in contact with microorganisms, whether from the environment or through direct contamination, are more likely to support biofilm formation. This article describes examples of surfaces that are conducive to microbial biofilm formation.

[0072] Methods for assessing biofilm formation are well known in the art and are described herein. Crystal violet is commonly used in microbiology for staining and visualizing biofilms; exemplary assays are as follows:

[0073] Preparation of nail cover plate

[0074] The nail cap consists of a porous plate, where each well contains a nail (a small, cylindrical plastic protrusion) instead of a flat bottom. These nails provide a surface for biofilm formation. The nail cap is designed to fit the corresponding well of a standard microtiter plate.

[0075] Microbial inoculation

[0076] The microorganism of interest, typically bacteria or fungi, is inoculated into each well of a microtiter plate containing a suitable growth medium. Each well of the microtiter plate corresponds to a pin on a pin cap. This allows the microorganism to adhere to the pin surface and form a biofilm on it.

[0077] Incubation

[0078] The nail caps were then inverted and placed on a microtiter plate containing inoculated microorganisms, ensuring that each nail was submerged in the culture medium. The assembled assembly was then incubated under conditions conducive to biofilm formation, allowing the microorganisms to grow and form a biofilm on the nail surface.

[0079] deal with :

[0080] Treatments such as antimicrobial agents or inhibitors can be added to the wells containing microorganisms before or during incubation to assess their impact on biofilm formation.

[0081] Crystal violet staining

[0082] After an appropriate incubation period (typically 24 to 48 hours), carefully remove the nail cover plate from the microtiter plate and gently rinse the nails to remove any non-adherent cells. Then immerse the nails in crystal violet solution, which stains the biofilm formed by adhering microorganisms.

[0083] destaining

[0084] Wash away excess crystal violet and gently rinse the nails to remove any unbound dye. Crystal violet bound to the biofilm remains on the nail surface.

[0085] Quantitative

[0086] The nails are transferred to a clean microtiter plate, and the crystal violet bound to the biofilm is dissolved using a suitable solvent (usually ethanol or acetic acid). The absorbance of the dissolved crystal violet solution is then measured spectrophotometrically at an appropriate wavelength (typically around 590 nm). The resulting absorbance value is proportional to the biofilm biomass formed on the nails, thus allowing for quantification of biofilm formation.

[0087] Biofilm formation can be measured in a high-throughput manner using nail cap and crystal violet staining, enabling simultaneous screening of multiple conditions, treatments, or microbial strains. The efficacy of an agent in inhibiting biofilm formation can be determined by comparing the absorbance values ​​of treated samples with untreated controls. The degree of activity can be quantified as the percentage reduction in absorbance / biomass. For example, if the absorbance is significantly reduced at certain concentrations compared to the untreated control, the agent can be considered to have significant biofilm inhibitory activity.

[0088] Biofilms are not unique to bacteria; many other microorganisms, as well as some multicellular organisms, can also produce them. Examples include various fungi, including *Candida albicans* and *Aspergillus fumigatus*, which are capable of forming biofilms. These fungal biofilms are often associated with infection, particularly in immunocompromised individuals. Certain protozoa (such as those belonging to the genera *Giardia* and *Entamoeba*) can form biofilms in aquatic environments and within the host's gastrointestinal tract. Algae (such as diatoms and green algae species) can form biofilms on submerged surfaces, including rocks, aquatic plants, and artificial substrates. Some viruses have been shown to form biofilms under certain conditions. For example, bacteriophages (viruses that infect bacteria) can adhere to surfaces and form biofilms composed of viral particles. Some multicellular organisms (such as marine invertebrates like corals, sponges, and mussels) can form biofilms with the help of symbiotic bacteria. These biofilms play important roles in the ecology and physiology of these organisms. Biofilms produced by non-bacterial organisms often have similar characteristics to bacterial biofilms, including the formation of extracellular polymers (EPS) that provide structural support and protection for the biological community within the biofilm.

[0089] In one embodiment, the agent effectively reduces and / or prevents and / or reverses microbial biofilm formation in microorganisms capable of producing amyloid fibrils. In one embodiment, the microorganism is selected from the group consisting of bacteria, fungi, protozoa, algae, viruses, and multicellular organisms. In one embodiment, the microorganism is bacteria. In one embodiment, the agent effectively reduces and / or prevents and / or reverses bacterial biofilm formation. Exemplary microorganisms are described herein.

[0090] In one implementation, the agent effectively reduces and / or prevents and / or reverses bacterial biofilm formation in bacteria capable of producing amyloid fibrils. For example, *Escherichia coli* can produce curli amyloid fibrils, which are involved in cell-cell adhesion and biofilm formation. These fibrils are composed of the major curli subunit protein CsgA. Similar to *E. coli*, *Salmonella enterica* can produce curli amyloid fibrils, which contribute to biofilm formation and host colonization. Staphylococcus species (such as *Staphylococcus aureus*) can generate amyloid fibrils composed of Bap proteins (biofilm-associated proteins), which contribute to biofilm formation and adhesion to surfaces. Bacillus species can produce amyloid fibrils called TasA fibrils, which are involved in biofilm formation and stability. *Pseudomonas aeruginosa* is known to produce amyloid fibrils composed of FapC proteins, which promote biofilm formation and persistence in chronic infections. Klebsiella pneumoniae is known to produce the amyloid component mycotoxin E492. Streptococcus is known to produce amyloid components P1, WapA, and SMU_63C. Vibrio cholerae is known to produce the amyloid component RbmA. Mycobacterium tuberculosis is known to produce the amyloid component MTP. Gallic bacillus anatis is known to produce the amyloid component Tu elongation factor. Xanthomonas anxidopidos is known to produce the amyloid component HpaG. Solibacillus silvestris AM1 is known to produce the amyloid component BE-AM1. Streptomyces coelicolor is known to produce the amyloid components Rodlins and Chaplins.

[0091] In one embodiment, the bacteria capable of producing amyloid fibrils are selected from the group consisting of: Staphylococcus species, Salmonella enterica, Pseudomonas species, Escherichia coli, Streptococcus mutans, Klebsiella pneumoniae, Legionella pneumophila, Vibrio cholerae, Bacillus species, Mycobacterium tuberculosis, Avian avian bacillus, Xanthomonas anxidopidos, Forest soil Bacillus AM1, and Streptomyces azureii.

[0092] It should be understood that by inhibiting the formation of amyloid in microorganisms, the agent can disrupt the integrity of the biofilm in microorganisms, thereby making the microorganisms sensitive to treatments such as antibiotic treatment.

[0093] In one embodiment, the method and use for reducing and / or preventing and / or reversing microbial biofilm formation further include contacting a microbial biofilm, or a surface that may be susceptible to microbial biofilm formation, with another antimicrobial agent. Examples of antimicrobial agents are described herein.

[0094] In one embodiment, the agent is capable of reducing and / or preventing and / or reversing bacterial biofilm formation in different bacterial species.

[0095] In one embodiment, reducing and / or preventing and / or reversing microbial biofilm formation includes contacting a biofilm present on a surface, or a surface that may be prone to biofilm formation, with an effective amount of the agent. In one embodiment, the surface is located outside a human or animal body. The surface may be impregnated with the agent, coated with the agent, or a combination thereof. The surface may be biological or non-biological. Examples of biological surfaces include, but are not limited to, animal or plant surfaces. Examples of non-biological surfaces include any media used in articles, such as plastics, glass, or metals, such as: prostheses, floors, workbenches, soil, dental instruments and equipment (such as dental water lines, dental tools, dentures, dental retainers, orthodontic appliances), medical devices, medical equipment (such as catheters, implants, and surgical instruments), contact lenses and lens cases, bandages, tissue dressings, surfaces (such as tabletops, countertops, bathtubs, tiles, filters (such as water filters), membranes (such as reverse osmosis membranes), fabrics (such as odor-resistant fabrics), pipes, drains, conduits (such as water pipes, gas pipes, oil pipes, drill pipes, fracturing pipes, sewage pipes, drain pipes), water tanks, hoses, fish tanks, showers, children's toys, ship hulls, cooling water systems, and heating water systems (including cooling towers).

[0096] In some implementations, the number of CFUs on a surface after contact with the agent can be reduced by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or 100% compared to the number of bacterial colony-forming units (CFUs) on the surface just before contact with the agent.

[0097] Methods for determining the number of bacterial colony-forming units (CFU) on a surface are well known in the art. A general scheme is provided herein.

[0098] (1) Collect samples from the target surface using a sterile swab, inoculation loop, or other suitable device. Ensure that the sampling method does not introduce contamination.

[0099] (2) Transfer the collected samples to a sterile liquid culture medium (such as saline solution or sterile broth) to suspend the bacteria.

[0100] (3) To reduce the number of bacteria in the sample to a countable level, serial dilutions are performed. This involves diluting the sample multiple times with a sterile diluent. Each dilution is then inoculated onto an agar plate.

[0101] (4) After dilution, inoculate equal aliquots of the diluted sample onto agar plates using techniques such as spread plate or pour plate methods. Ensure that the agar plates are suitable for the type of bacteria you are trying to count and that they provide optimal conditions for bacterial growth.

[0102] (5) Incubate the agar plates at a temperature suitable for the bacteria being studied. This temperature may be room temperature, body temperature, or another specific temperature, depending on the bacterial species.

[0103] (6) After an appropriate incubation period (usually 24-48 hours), count the number of bacterial colonies visible on the agar plate. Each colony represents a single live bacterial cell from the original sample.

[0104] (7) Calculate the number of CFU per unit area or volume based on the dilution factor and the number of colonies counted on each plate.

[0105] (8) Finally, the results are reported as CFU per unit area or volume of the original sample.

[0106] It should be understood that the above method can be used to compare the number of CFUs present on the surface before and after the surface comes into contact with the agent.

[0107] In one aspect, the present invention provides an N-terminal region comprising CagA (CagA N CagA or a portion thereof or a variant thereof, or an agent comprising thereof, wherein the N-terminal region of CagA or a portion thereof or a variant thereof is capable of reducing and / or preventing and / or reversing amyloid formation, for medical use.

[0108] In one aspect, the present invention provides an N-terminal region comprising CagA (CagA N CagA or a portion thereof or a variant thereof, or an agent comprising thereof, wherein the N-terminal region of CagA or a portion thereof or a variant thereof is capable of reducing and / or preventing and / or reversing amyloid formation, for the prevention and / or treatment of diseases or conditions characterized by amyloid formation.

[0109] In one aspect, the present invention provides a method for preventing and / or treating a disease or condition characterized by amyloid formation in a subject, the method comprising administering to the subject an effective amount of an N-terminal region containing CagA (CagA NCagA, or a portion thereof or a variant thereof, or an agent comprising thereof, wherein the N-terminal region of CagA, or a portion thereof or a variant thereof, is capable of reducing and / or preventing and / or reversing amyloid formation.

[0110] In one aspect, the present invention provides an N-terminal region comprising CagA (CagA N The use of CagA, or a portion thereof or a variant thereof, or an agent thereof, in the preparation of a medicament for the prevention and / or treatment of a disease or condition characterized by amyloid formation, wherein the N-terminal region of CagA, or a portion thereof or a variant thereof, is capable of reducing and / or preventing and / or reversing amyloid formation.

[0111] "Diseases or conditions characterized by amyloid formation" includes any medical condition promoted by the production and / or accumulation of amyloid fibrils. Amyloid fibrils can be pathological amyloid fibrils, which can lead to the development of neurodegenerative diseases as described herein, or functional amyloid fibrils, which can lead to biofilm formation during microbial infections.

[0112] In one implementation, the disease or condition characterized by amyloid formation is a microbial infection that produces a biofilm in the subject.

[0113] "Biofilm-forming microbial infections in subjects" encompasses infections caused by microorganisms capable of producing biofilms, where the biofilm provides a barrier to enhance the microorganism's resistance to antibiotics and the body's immune system. Biofilm-associated infections are often chronic and difficult to treat, leading to persistent or recurrent infections. Reducing the biofilm increases the microorganism's sensitivity to antimicrobial agents. Prophylactic or therapeutic reduction of biofilm structures can be achieved by preventing the initial formation of biofilms or by disrupting existing biofilms.

[0114] Microbial infections and diseases treatable by the methods of this invention include those caused by any microorganism capable of forming biofilms. Non-limiting examples of such microorganisms include *Streptococcus agalactiae*, *Neisseria meningitidis*, *Treponema* (*Treponema denticola*, *Treponema pallidum*), *Burkholderia cepacia*, or *Burkholderia pseudomallei*.

[0115] Microbial infections can be one or more of the following: Haemophilus influenzae (untyped), Moraxella catarrhalis, Streptococcus pneumoniae, Streptococcus pyogenes, Pseudomonas aeruginosa, and Mycobacterium tuberculosis. These microbial infections may be present in the upper, middle, and lower respiratory tracts (otitis, sinusitis, bronchitis, and exacerbations of chronic obstructive pulmonary disease (COPD), chronic cough, complications and / or primary causes of cystic fibrosis (CF), and community-acquired pneumonia (CAP)). Infections may also occur in the oral cavity (dental caries, periodontitis) and may be caused by Streptococcus mutans, Porphyromonas gingivalis, or Aggregatibacter actinomycetemcomitans. In this example, the medication can be formulated into mouthwash or toothpaste.

[0116] Infections may also be localized to the skin (abscess, "staphylococcal" infection, impetigo, secondary burn infection, Lyme disease) and are caused by Staphylococcus aureus, Staphylococcus epidermidis, Pseudomonas aeruginosa, and Borrelia burdorferi. In this example, the agent is formulated for topical application.

[0117] Urinary tract infections (UTIs) can also be treated and are usually caused by *Escherichia coli*. Gastrointestinal (GI) infections (diarrhea, cholera, gallstones, gastric ulcers) are usually caused by *Salmonella enterica serovar*, *Vibrio cholerae*, and *Helicobacter pylori*. Genital tract infections include and are usually caused by *Neisseria gonorrhoeae*. Infections can be bladder infections or indwelling device infections caused by *Enterococcus faecalis*. Infections associated with implanted prosthetic devices (such as artificial hip or knee replacements, or dental implants) or medical devices (such as pumps, catheters, stents, or monitoring systems), usually caused by various bacteria, can be treated by the methods of the present invention. These devices can be coated with or conjugated with the agents described herein. Infections caused by *Streptococcus agalactiae* can also be treated by the methods of the present invention, and are a major cause of bacterial sepsis in newborns. Infections caused by *Neisseria meningitidis*, which can cause meningitis, can also be treated. Therefore, by implementing the method of the present invention, these diseases and complications caused by these infections can also be prevented or treated.

[0118] Examples of treatable subjects include humans, rodents (mice and rats), and domesticated livestock (such as cattle, pigs, horses, and poultry species). Treatment of subjects can result in a reduction in the amount of microorganisms (e.g., the number of colony-forming units (CFU)) in or on the subject's body.

[0119] The reduction compared to the subject before administration can be at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90%. In this regard, the term "effective amount" refers to an amount sufficient to produce the desired effect of reducing microbial biomass.

[0120] In one embodiment, the method and use for preventing and / or treating microbial infections that produce biofilms in a subject further include administering an antimicrobial agent to a subject suffering from a microbial infection that produces biofilms.

[0121] Examples of antimicrobial agents include antibiotics, preservatives, and disinfectants. Also included are enzymes such as dispersin B and DNases, which degrade extracellular polymeric substances (EPS) that hold biofilms together, weaken their structure, and facilitate their removal. Antimicrobial peptides (AMPs) that exhibit antimicrobial activity against a variety of microorganisms, including those within biofilms, are also included. Quorum sensing inhibitors (QSIs) that interfere with intercellular bacterial communication mechanisms, thereby disrupting quorum sensing and inhibiting biofilm formation are also included. Metal ions such as silver, copper, and zinc possess antimicrobial properties and can disrupt biofilm formation and viability. Surfactants disrupt biofilm structure by interfering with cell adhesion and biofilm matrix formation. Bacteriophages can target and lyse biofilm-associated bacteria.

[0122] Examples of antibiotics include rifampin, vancomycin, ciprofloxacin, doxycycline, kanamycin, amikacin, gentamicin, tobramycin, erythromycin, and clindamycin.

[0123] This document describes a method for administering the pharmaceutical agent of the present invention to a subject. In one embodiment, an effective amount of the pharmaceutical agent is administered to the subject.

[0124] In one implementation, the disease or condition characterized by amyloid formation is a protein misfolding disease.

[0125] "Protein misfolding disorders" encompass conditions characterized by the accumulation of misfolded proteins in a subject's body. Normally, proteins fold into specific three-dimensional shapes, which are essential for their normal function. However, in protein misfolding disorders, gene mutations, environmental factors, or age-related changes can cause proteins to misfold or malfold. Misfolded proteins tend to aggregate and form insoluble structures (such as amyloid fibrils or inclusion bodies) that can accumulate within eukaryotic and prokaryotic cells or in the extracellular space, thereby disrupting normal cellular function. Examples of protein misfolding disorders include Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis (ALS), and prion diseases such as Creutzfeldt-Jakob disease (CJD).

[0126] In one implementation, the disease or condition characterized by the formation of amyloid material is amyloidosis.

[0127] "Amyloidosis" encompasses the meaning of protein misfolding diseases, characterized by proteins abnormally folding into structurally abnormal conformations. In these diseases, proteins cannot adopt their native three-dimensional structures, leading to the formation of insoluble aggregates or toxic intermediates.

[0128] Fibrous amyloid structures are associated with approximately 40 human diseases, particularly neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), as well as systemic diseases such as type 2 diabetes (Sipe, JD et al., International Society of Amyloidosis 2016 Nomenclature Guidelines. Amyloid 23, 209-213 (2016)). In one embodiment, protein misfolding diseases are mediated by any of the amyloid fibrils and / or intracellular protein inclusions listed in Tables 1 and 2.

[0129] In one implementation, protein misfolding diseases are selected from the group consisting of: tau protein diseases, such as Alzheimer's disease and frontotemporal dementia, Parkinson's disease (PD) and other synucleinic diseases, Huntington's disease, familial amyloid polyneuropathy (FAP), senile systemic amyloidosis, amyotrophic lateral sclerosis (ALS), prions, dialysis-associated amyloidosis, secondary (reactive) amyloidosis, hereditary amyloidosis (AApoAI amyloidosis), familial amyloidosis, Finnish-type hereditary amyloidosis, hereditary nonneuropathy-related systemic amyloidosis, systemic immunoglobulin light chain amyloidosis, immunoglobulin heavy chain amyloidosis (AH), and hereditary renal amyloidosis.

[0130] Alzheimer's disease is characterized by the accumulation of misfolded amyloid-β (Aβ) and tau proteins in the brain, leading to neuronal dysfunction and cognitive decline. α-synuclein is an abundant protein in neuronal cells and is involved in the formation of Lewy bodies, characteristic pathological aggregates found in Parkinson's disease and other synucleinic disorders. Tau protein is primarily found in neurons and participates in stabilizing microtubules. In tau-related diseases such as Alzheimer's disease and frontotemporal dementia, tau protein undergoes abnormal phosphorylation and forms intracellular neurofibrillary tangles. Huntington's disease is caused by the amplification of the CAG repeat sequence in the huntingtin (HTT) gene, resulting in the production of misfolded mutant huntingtin protein. The accumulation of mutant huntingtin protein leads to neuronal dysfunction and neurodegeneration. Transthyretin (TTR) is a transporter protein primarily produced by the liver and is associated with familial amyloid-polyneuropathy (FAP) and age-related systemic amyloidosis. Amyotrophic lateral sclerosis (ALS) is caused by misfolded proteins such as superoxide dismutase 1 (SOD1) or TDP-43, which accumulate in motor neurons, leading to motor neuron degeneration and muscle weakness. Prion diseases (such as Creutzfeldt-Jakob disease (CJD) and variant CJD (vCJD)) involve the misfolding of normal prion protein (PrP^C) into an aberrant isoform (PrP^Sc), which can proliferate and induce further protein misfolding. Pancreatic amyloid polypeptide (IAPP or pancreatic amyloid) is co-secreted by pancreatic β-cells with insulin and is involved in the regulation of glucose homeostasis. In type 2 diabetes, IAPP aggregates within the islets into amyloid fibrils. Prion protein (PrP) is primarily known for its role in prion diseases such as Creutzfeldt-Jakob disease (CJD) and bovine spongiform encephalopathy (BSE or "mad cow disease"). β-2 microglobulin (β2M) is a component of major histocompatibility complex (MHC) class I molecules and is associated with dialysis-associated amyloidosis in patients with end-stage renal disease. Serum amyloid A (SAA) is an acute-phase protein produced due to an inflammatory response and is associated with secondary (reactive) amyloidosis. Apolipoprotein AI (apoAI) is associated with hereditary amyloidosis (AApoAI amyloidosis). Gel protein (AGel) is associated with familial amyloidosis and the Finnish type (Finnish hereditary amyloidosis). Lysozyme is associated with hereditary nonneurotic systemic amyloidosis. Systemic immunoglobulin light chain amyloidosis is a protein misfolding disease caused by the transformation of immunoglobulin light chains from their soluble functional state into highly organized amyloid fibrous aggregates (leading to organ dysfunction). Immunoglobulin heavy chain amyloidosis (AH) is an amyloidosis caused by the deposition of monoclonal immunoglobulin heavy chains. Fibrinogen Aα chain (AFib) is associated with hereditary renal amyloidosis.

[0131] As used herein, “administration” means placing a composition or agent disclosed herein into a subject by a method or route that enables at least partial delivery of the agent to the desired site. Pharmaceutical compositions comprising compounds disclosed herein may be administered via any suitable route to achieve effective treatment in a subject.

[0132] In one embodiment, the method and use for preventing and / or treating a protein misfolding disease in a subject further include the administration of additional therapeutic components. These additional therapeutic components include those already identified for the prevention and / or treatment of protein misfolding diseases, including those described herein.

[0133] It should be understood that the pharmaceutical agents of the present invention can be used in combination with established Alzheimer's disease treatments aimed at relieving symptoms, such as cholinesterase inhibitors (e.g., donepezil, rivastigmine, galantamine) and NMDA receptor antagonists (e.g., memantine). Since Alzheimer's disease involves Aβ plaques and tau tangles, the pharmaceutical agent can be part of a regimen that also includes experimental treatments such as tau aggregation inhibitors or monoclonal antibodies targeting Aβ or tau. For Parkinson's disease, the pharmaceutical agent of the present invention can be administered in combination with dopaminergic drugs (e.g., levodopa, or dopamine receptor agonists such as pramipexole, ropinirole, etc.), which are standard treatments for controlling motor symptoms. MAO-B inhibitors that prevent the breakdown of dopamine in the brain (e.g., selegiline, rasagiline) can also be used as part of combination therapy. For type II diabetes, the pharmaceutical agent of the present invention can be used in combination with insulin or insulin analogs in patients requiring insulin therapy. Other antidiabetic drugs such as metformin, sulfonylureas, GLP-1 receptor agonists (e.g., liraglutide) and SGLT2 inhibitors (e.g., canagliflozin) can also be part of the treatment regimen.

[0134] The administration of medications and other treatment components can be sequential or simultaneous. The administration regimen and method can be those that physicians typically or conventionally use for that other treatment component.

[0135] In one embodiment, methods and uses for preventing and / or treating protein misfolding diseases in a subject also include formulating an agent for delivery across the blood-brain barrier. Methods for formulating drugs to enable them to cross the blood-brain barrier are known in the art, for example, as described in Wu, D. et al., The blood–brain barrier: structure, regulation, and drug delivery. Sig Transduct Target Ther 8, 217 (2023), the entire text of which is incorporated herein by reference. Such methods include formulating drugs with lipid-based carriers, such as liposomes, micelles, or lipid nanoparticles, which can improve the solubility, stability, and transport of the drug across the blood-brain barrier (BBB). Encapsulating drugs within nanoparticles can protect them from degradation and facilitate their transport across the BBB. Nanoparticles can be engineered through surface modifications to target specific receptors or utilize endocytosis pathways, thereby enhancing their ability to penetrate the BBB. Conjugating drugs to endogenous transport substrates recognized by transport proteins expressed at the BBB can facilitate drug entry into the brain. For example, amino acid or glucose transport systems can be used to transport drugs across the brain's blood-brain barrier (BBB). Receptor-mediated transcytosis involves targeting specific receptors expressed on the surface of brain endothelial cells to trigger vesicular transport of drugs across the BBB. Ligands or antibodies that bind to these receptors can conjugate drugs to facilitate their transport into the brain.

[0136] In one aspect, the present invention provides an N-terminal region comprising CagA (CagA N CagA, or a portion thereof or a variant thereof, or an agent comprising thereof, wherein the N-terminal region of CagA, or a portion thereof or a variant thereof, is capable of reducing and / or preventing and / or reversing amyloid formation.

[0137] In one implementation, the N-terminal region of CagA (CagA) is capable of reducing and / or preventing and / or reversing amyloid formation. N (or its parts or variants are separate or recombined.)

[0138] With regard to peptides and proteins, "isolated" includes the meaning of peptides and proteins isolated from other cellular proteins, and is intended to encompass both purified and recombinant peptides. In other embodiments, the term "isolated or recombinant" means isolated from components, cells, and other substances, wherein cells, tissues, polynucleotides, peptides, polypeptides, proteins, antibodies, or fragments thereof are normally found in nature.

[0139] The isolated peptides and proteins are intended to include wild-type and recombinant peptides and proteins isolated from prokaryotic and eukaryotic host cells, as well as their mutant proteins, analogs, and fragments.

[0140] On the other hand, proteins are conjugated or linked to detectable tags. Suitable tags are known in the art.

[0141] The pharmaceutical agents of the present invention may comprise or consist of fusions or conjugates, wherein such fusions or conjugates contain the N-terminal region of CagA (CagA N CagA, or a portion thereof or variants thereof, and proteins having or comprising anti-amyloid or antimicrobial activity, wherein the N-terminal region of CagA, or a portion thereof or variants thereof, is capable of reducing and / or preventing and / or reversing amyloid formation. Proteins having anti-amyloid activity and proteins having antimicrobial activity are known in the art, and examples are provided herein.

[0142] Furthermore, the pharmaceutical agents of the present invention may comprise or consist of fusions or conjugates, which contain the N-terminal region of CagA (CagA N The N-terminal region of CagA, or a portion thereof or a variant thereof, along with a tag sequence (such as a peptide that facilitates purification), is capable of reducing and / or preventing and / or reversing amyloid formation. For example, the tag amino acid sequence can be a hexahistine peptide, such as the tag provided in pQE vectors (QIAGEN, Inc.), many of which are commercially available. As described in Gentz ​​et al., 1989, Proc. Natl. Acad. Sci. USA 86:821-824, hexahistine, for example, provides convenient purification of fusion proteins. Other peptide tags for purification include, but are not limited to, hemagglutinin (“HA”) tags (which correspond to an epitope derived from influenza hemagglutinin protein (Wilson et al., 1984, Cell 37:767)) and “FLAG” tags. Proteins can be linked to solubility tags for enhancing solubility, including thioredoxin tags and NT* tags (Kronqvist, N. et al., Nat Commun 8, 15504 (2017)). Fusion tags used to express systems such as protein solubility, purification, and immunogenicity in bacteria are known in the art, such as those described in Costa S et al., (2014) Front. Microbiol. 5:63, which is incorporated herein by reference in its entirety.

[0143] In one aspect, the present invention provides polynucleotides encoding polypeptides as described herein, such polypeptides having at least 70% sequence identity with the amino acid sequence of SEQ ID NO: 2 and capable of reducing and / or preventing and / or reversing amyloid formation, and / or their fusions and / or conjugates as described herein.

[0144] The polynucleotide may encode a polypeptide having at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with the amino acid sequence of SEQ ID NO: 2.

[0145] The polynucleotides encoding the polypeptides described herein can be readily determined by those skilled in the art by referring to the standard genetic code, where different nucleotide triplets (codons) are known to encode specific amino acids. As will be apparent to those skilled in the art, due to the degeneracy of the genetic code, the variety of nucleotide sequences encoding any of the proteins described herein is vast, but also finite.

[0146] In one aspect, the present invention provides a vector comprising a polynucleotide as described herein. The vector is a replicative polynucleotide, such as a plasmid, bacteriophage, or granule, to which another polynucleotide may be attached to induce replication of the attached polynucleotide. The construction of the polynucleotide-containing vector employs standard ligation techniques known in the art. See, for example, Sambrook et al., Molecular Cloning: A Laboratory Manual., Cold Spring Harbor Laboratory Press (1989). The vector can be used for further cloning (amplification of the polynucleotide), i.e., a cloning vector, or for expression of the polynucleotide, i.e., an expression vector. “Vector” includes plasmid vectors, viral vectors, granule vectors, and artificial chromosome vectors. Examples of viral vectors include, for example, adenovirus vectors, adeno-associated virus vectors, lentiviral vectors, retroviral vectors, and herpesvirus vectors. Typically, the vector is capable of replication in a microbial host (e.g., prokaryotic bacteria, such as *Escherichia coli*). Preferably, the vector is a plasmid. The vector may be an expression vector.

[0147] The choice of vector depends on several desired characteristics in the resulting construct, such as selection markers and vector replication rate. In some respects, suitable host cells for cloning or expressing the vectors described herein include eukaryotic cells, such as CHO cells, HEK cells, and insect cells. Suitable host cells for cloning or expressing the vectors described herein include prokaryotic cells. Suitable prokaryotic cells include eubacteria, such as Gram-negative microorganisms, for example, *Escherichia coli*.

[0148] Vectors can be introduced into host cells using methods known and routinely used by those skilled in the art. For example, calcium phosphate precipitation, transfection, electroporation, heat shock, lipid transfection, microinjection, and virus-mediated nucleic acid transfer are common methods for introducing nucleic acids into host cells.

[0149] Polynucleotides can be produced in vitro or in vivo. For example, methods for in vitro synthesis include, but are not limited to, chemical synthesis using conventional DNA / RNA synthesizers. Commercial suppliers of polynucleotides and reagents used in such synthesis are well known.

[0150] The expression vector optionally includes a regulatory sequence operatively linked to the coding region. This disclosure is not limited to the use of any particular promoter, and a variety of promoters are known. The promoter acts as a regulatory signal that binds to RNA polymerase in the cell to initiate transcription of the downstream (3' direction) coding region. The promoter used can be constitutive or inducible. It can be, but does not have to be, heterologous relative to the host cell.

[0151] The expression vector may optionally include a ribosome binding site and a start site (e.g., codon ATG) to initiate the translation of transcriptional information to produce a polypeptide. It may also include a termination sequence to end translation. The termination sequence is typically the absence of a corresponding aminoacetyl-tRNA codon, thereby terminating polypeptide synthesis. The polynucleotide used for transforming host cells may optionally further include a transcription termination sequence.

[0152] Vectors introduced into host cells optionally include one or more marker sequences, which typically encode molecules that are inactivated or otherwise detected by compounds in the growth medium or detected by compounds in the growth medium. For example, including a marker sequence may confer resistance to antibiotics to transformed cells, or it may confer compound-specific metabolism to transformed cells. Examples of marker sequences are sequences that confer resistance to kanamycin, ampicillin, chloramphenicol, tetracycline, and neomycin.

[0153] In one aspect, the present invention provides a combination of a pharmaceutical agent as defined herein and an antimicrobial agent as defined herein.

[0154] In one embodiment, the combination of the pharmaceutical agent and the antimicrobial agent is provided in a separate container and / or a separate composition. In another embodiment, the combination of the pharmaceutical agent and the antimicrobial agent is formulated into a composition. In one embodiment, the antimicrobial agent is an antibiotic. Exemplary antimicrobial agents and antibiotics are described herein.

[0155] In one embodiment, the composition is formulated for use as a coating. The coating can be used to cover a surface, can be incorporated into (e.g., impregnated) into the surface, or a combination of both. The proteins described herein can be combined with agents suitable for coating surfaces, such as, but not limited to, polymers, plasticizers, pigments, colorants, flow aids, stabilizers, pore-forming agents, and / or surfactants. Examples of polymers that can be used as coating agents include, but are not limited to, cellulose polymers such as cellulose acetate phthalate, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, hydroxypropyl methyl cellulose phthalate, and hydroxypropyl methyl cellulose acetate succinate; polyvinyl acetate phthalate, polyurethane, epoxy resins, acrylic polymers and copolymers, methacrylic resins, zein, shellac, and polysaccharides.

[0156] In one embodiment, the composition is formulated for use as a cleaning solution. This composition is suitable for application to a surface to clean and / or disinfect the surface. The proteins described herein can be formulated as solutions in suitable solvents for application in spray bottles, serving as aerosols or foams suitable for application to surfaces.

[0157] In one embodiment, the composition used as a cleaning / disinfecting solution includes, in addition to the agents described herein, an acceptable carrier and an antimicrobial agent. In another embodiment, the composition used as a cleaning / disinfecting solution includes, in addition to the agents described herein, a cleaning agent, a disinfectant, or a combination thereof. The antimicrobial agent can be either microbial-killing or microbial-inhibiting. Antimicrobial agents that can be incorporated into cleaning formulations are known in the art and include quaternary ammonium compounds (QACs), which are chemical substances used to kill bacteria, viruses, and molds. Methods for preparing formulations used as disinfectants are known in the art.

[0158] Examples of surfaces that can be coated and / or disinfected with the compositions described herein can be biological or non-biological. Examples of biological surfaces include, but are not limited to, animal or plant surfaces. Examples of non-biological surfaces include any media used in articles, such as plastics, glass, or metals, for example: prostheses, floors, workbenches, soil, dental instruments, teeth, dentures, dental retainers, orthodontic appliances including plastic orthodontic appliances, medical devices, medical equipment (e.g., endoscopes), contact lenses and lens cases, catheters, bandages, tissue dressings, surfaces (e.g., tabletops, countertops, bathtubs, tiles), filters (e.g., water filters), membranes (e.g., reverse osmosis membranes, etc.), fabrics (e.g., odor-resistant fabrics), pipes, drains, conduits (including water pipes, gas pipes, oil pipes, drill pipes, fracturing pipes, sewage pipes, drain pipes), hoses, aquariums, showers, children's toys, ship hulls, cooling water systems, and heating water systems (including cooling towers).

[0159] In one aspect, the present invention provides a pharmaceutical composition comprising a pharmaceutical agent as defined herein and a pharmaceutically acceptable carrier, diluent, and / or excipient.

[0160] As used herein, the term "pharmaceutical composition" refers to an active agent in combination with a pharmaceutically acceptable carrier (e.g., a carrier commonly used in the pharmaceutical industry). The phrase "pharmaceutically acceptable" is used herein to mean those compounds, substances, compositions, and / or dosage forms suitable for contact with human and animal tissues to a reasonable extent of medical judgment, without excessive toxicity, irritation, allergic reactions, or other problems or complications, and in proportion to a reasonable benefit / risk ratio.

[0161] Pharmaceutical compositions containing the agents of the present invention provided herein can be prepared by mixing an agent having the desired purity with an optional physiologically acceptable carrier, excipient, or stabilizer for storage in the form of a lyophilized formulation or an aqueous solution (Remington's Pharmaceutical Sciences (1990) Mack Publishing Co., Easton, Pa.). Acceptable carriers, excipients, or stabilizers are non-toxic to the recipient at the doses and concentrations used and include buffers such as phosphates, citrates, and other organic acids; antioxidants, including ascorbic acid and methionine; preservatives (such as octadecyl dimethyl benzyl ammonium chloride; hexamethyl diammonium chloride; benzalkonium chloride, benzyl chloride; phenol, butanol, or benzyl alcohol; alkyl esters of p-hydroxybenzoate, such as methylparaben or propylparaben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol); low molecular weight (less than about 10). (Residues) polypeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers, such as polyvinylpyrrolidone; amino acids, such as glycine, glutamine, asparagine, histidine, arginine, or lysine; monosaccharides, disaccharides, and other carbohydrates, including glucose, mannose, or dextrin; chelating agents, such as EDTA; sugars, such as sucrose, mannitol, trehalose, or sorbitol; salt-forming counterions, such as sodium; metal complexes (e.g., Zn-protein complexes); and / or nonionic surfactants, such as TWEEN. ™ PLURONICS ™ Or polyethylene glycol (PEG).

[0162] The composition (such as those described herein) may also contain more than one active compound, as necessary for the specific indication being treated. In some embodiments, the composition comprises or consists of the pharmaceutical agent described herein and one or more active compounds having complementary activities that do not adversely affect each other. Such molecules are suitably present in amounts effective for the intended purpose. For example, the pharmaceutical agent of the present invention may be combined with one or more other therapeutic components. Such combination therapy may be administered to the patient sequentially, simultaneously, or sequentially.

[0163] The pharmaceutical compositions provided herein contain a therapeutically effective amount of the pharmaceutical agent described herein. The pharmaceutical agent of the present invention is contained in a pharmaceutically acceptable carrier in an effective amount sufficient to exert a therapeutically useful effect on the treated subject without undesirable side effects. Therapeuticly effective concentrations can be empirically determined by testing the compound in vitro and in vivo systems using conventional methods, and the dosage for human use can be extrapolated accordingly.

[0164] In one embodiment, the composition is formulated for single-dose administration. To formulate the composition, a fraction by weight of the compound is dissolved, suspended, dispersed, or otherwise mixed in a selected carrier at an effective concentration to relieve, prevent, or improve one or more symptoms of the condition being treated. The pharmaceutical agent can be formulated and administered in single-dose or multi-dose form. As used herein, a unit dosage form refers to a physically discrete unit that is suitable for human and animal subjects and is individually packaged as known in the art. Each unit dose contains a predetermined amount of the pharmaceutical agent sufficient to produce the desired therapeutic effect, as well as the desired pharmaceutical carrier, solvent, or diluent. Examples of unit dosage forms include ampoules and syringes, and individually packaged tablets or capsules. Unit dosage forms can be administered in fractions or multiples thereof. Multi-dose forms are multiple identical unit dosage forms packaged in a single container for administration in separate unit dosage forms. Examples of multi-dose forms include vials, bottles of tablets or capsules, or pints or gallons. Thus, multi-dose forms are multiple unit doses not separated in packaging.

[0165] In one embodiment, the therapeutically effective dose produces a serum concentration of the drug from about 0.1 ng / ml to about 50 μg / ml to 100 μg / ml. In another embodiment, the pharmaceutical composition provides a dose of about 0.001 mg to about 2000 mg of drug per kilogram of body weight per day. The pharmaceutical dosage unit can be prepared to provide a combination of about 0.01 mg, 0.1 mg, or 1 mg per dosage unit to about 100 mg, 500 mg, 1000 mg, or 2000 mg of the drug and / or other optional essential ingredients, and in one embodiment, a combination of about 10 mg to about 500 mg of the drug and / or other optional essential ingredients.

[0166] This medication can be administered once or divided into multiple smaller doses administered at regular intervals. It should be understood that the precise dosage and duration of treatment depend on the disease being treated and can be determined empirically using established testing protocols or extrapolated from in vivo or in vitro test data. It should be noted that concentration and dosage values ​​can also vary depending on the severity of the condition to be alleviated. It should also be understood that for any given subject, the specific dosage regimen can be adjusted over time based on individual needs and the professional judgment of the person administering or supervising the composition, and the concentration ranges described herein are merely exemplary and not intended to limit the scope or practice of the claimed compositions.

[0167] Dosage forms or compositions containing 0.005% to 100% antibodies, with the balance consisting of a non-toxic carrier, can be prepared. Methods for preparing these compositions are known to those skilled in the art.

[0168] Oral drug dosage forms are solid, gel, or liquid. Solid dosage forms include tablets, capsules, granules, and powders. Types of oral tablets include compressed chewable tablets, as well as tablets that may be enteric-coated, sugar-coated, or film-coated. Capsules may be hard or soft gelatin capsules, while granules and powders may be provided in non-effervescent or effervescent forms in combination with other ingredients known to those skilled in the art.

[0169] In some embodiments, the formulation is a solid dosage form. In some embodiments, the formulation is a capsule or tablet. Tablets, pills, capsules, lozenges, etc., may contain one or more of the following ingredients or compounds with similar properties: binders; lubricants; diluents; glidants; disintegrants; colorants; sweeteners; flavorings; wetting agents; emetic coatings; and film coatings. Examples of binders include microcrystalline cellulose, tragacanth gum, glucose solution, gum arabic paste, gelatin solution, molasses, polyvinylpyrrolidone, povidone, crospovidone, sucrose, and starch paste. Lubricants include talc, starch, magnesium stearate or calcium stearate, lycopoise, and stearic acid. Diluents include, for example, lactose, sucrose, starch, kaolin, salt, mannitol, and dicalcium phosphate. Glidants include, but are not limited to, colloidal silica. Disintegrants include croscarmellose sodium, carboxymethyl starch sodium, alginate, corn starch, potato starch, bentonite, methylcellulose, agar, and carboxymethyl cellulose. Colorants include, for example, any approved water-soluble FD and C dyes, mixtures thereof; and water-insoluble FD and C dyes suspended on alumina hydrate. Sweeteners include sucrose, lactose, mannitol, and artificial sweeteners such as saccharin, and any number of spray-dried flavorings. Flavorings include natural flavorings extracted from plants such as fruits and synthetic blends of compounds that produce a pleasant sensation, such as, but not limited to, peppermint and methyl salicylate. Wetting agents include propylene glycol monostearate, sorbitol monooleate, diethylene glycol monolaurate, and polyoxyethylene lauryl ether. Emetic coatings include fatty acids, fats, waxes, shellac, ammoniated shellac, and cellulose acetate phthalate. The film coating includes hydroxyethyl cellulose, sodium carboxymethyl cellulose, polyethylene glycol 4000, and cellulose acetate phthalate.

[0170] The pharmaceutical agents described herein are provided in compositional form that protects them from the acidic environment of the stomach. For example, the composition can be formulated in an enteric coating that maintains its integrity in the stomach and releases the active compound in the intestine. The composition can also be formulated in combination with antacids or other such ingredients.

[0171] When the dosage unit is in capsule form, it may contain liquid carriers such as fatty oils, in addition to the substances described above. Furthermore, the dosage unit form may contain various other substances that alter the physical form of the dosage unit, such as coatings of sugars and other enteric solvents. These compounds can also be administered as components of elixirs, suspensions, syrups, wafers, sprinkles, chewing gum, etc. Besides the active compounds, syrups may also contain sucrose as a sweetener and certain preservatives, dyes and colorants, and flavorings.

[0172] This pharmaceutical preparation may also be mixed with other active substances that do not impair the desired effect, or with substances that complement the desired effect, such as antacids, H2 blockers, and diuretics. The active ingredient is the pharmaceutical preparation as described herein or a pharmaceutically acceptable derivative thereof. Higher concentrations of the active ingredient, up to about 98% by weight, may be included.

[0173] In all embodiments, the tablet and capsule formulations may be coated as known to those skilled in the art to alter or maintain the dissolution of the active ingredient. Thus, for example, they may be coated with conventional enterically digestible coatings such as phenyl salicylate, waxes, and cellulose acetate.

[0174] The formulation may be a liquid dosage form. Liquid oral dosage forms include aqueous solutions, emulsions, suspensions, solutions and / or suspensions reconstituted from non-effervescent particles, and effervescent formulations reconstituted from effervescent particles. Aqueous solutions include, for example, elixirs and syrups. Emulsions are oil-in-water or water-in-oil emulsions. Elixirs are clarified, sweetened hydroalcoholic formulations. Pharmaceutically acceptable carriers used in elixirs include solvents. Syrups are concentrated aqueous solutions of sugars (e.g., sucrose) and may contain preservatives.

[0175] Pharmaceutically acceptable carriers for emulsions include non-aqueous liquids, emulsifiers, and preservatives. Suspensions use pharmaceutically acceptable suspending agents and preservatives.

[0176] Pharmaceutically acceptable substances used in non-effervescent granules to reconstitute into liquid oral dosage forms include diluents, sweeteners, and wetting agents. Pharmaceutically acceptable substances used in effervescent granules to reconstitute into liquid oral dosage forms include organic acids and carbon dioxide sources. Colorants and flavoring agents are used in all of the above dosage forms.

[0177] Solvents include glycerol, sorbitol, ethanol, and syrups. Examples of preservatives include glycerol, methylparaben and propylparaben, benzoic acid, sodium benzoate, and alcohols. Examples of non-aqueous liquids used in emulsions include mineral oil and cottonseed oil. Examples of emulsifiers include gelatin, gum arabic, tragacanth, bentonite, and surfactants such as polyoxyethylene sorbitol monooleate. Suspending agents include sodium carboxymethyl cellulose, pectin, tragacanth, colloidal magnesium aluminum silicate, and gum arabic. Sweeteners include sucrose, syrups, glycerol, and artificial sweeteners such as saccharin. Wetting agents include propylene glycol monostearate, sorbitol monooleate, diethylene glycol monolaurate, and polyoxyethylene lauryl ether. Organic acids include citric acid and tartaric acid. Sources of carbon dioxide include sodium bicarbonate and sodium carbonate. Colorants include any approved, certified water-soluble FD and C dyes, and mixtures thereof. Flavorings include natural spices extracted from plants such as fruits and synthetic blends of compounds that produce a pleasant taste.

[0178] For solid dosage forms, solutions or suspensions in, for example, propylene carbonate, vegetable oil, or triglycerides can be encapsulated in gelatin capsules. Such solutions and their preparation and encapsulation are disclosed in U.S. Patents 4,328,245; 4,409,239; and 4,410,545. For liquid dosage forms, solutions (e.g., polyethylene glycol solutions) can be diluted with a sufficient amount of a pharmaceutically acceptable liquid carrier (e.g., water) to facilitate dose-controlled administration.

[0179] Alternatively, liquid or semi-solid oral formulations can be prepared by dissolving or dispersing the active compound or salt in vegetable oils, glycols, triglycerides, propylene glycol esters (e.g., propylene carbonate), and other such carriers, and encapsulating these solutions or suspensions in hard or soft gelatin capsule shells. Other useful formulations include those shown in U.S. Patents RE28,819 and 4,358,603. In short, such formulations include, but are not limited to, formulations containing the pharmaceutical agents described herein, dialkylated monoalkylene glycols or polyalkylene glycols (including, but not limited to, 1,2-dimethoxymethane, diethylene glycol dimethyl ether, triethylene glycol dimethyl ether, tetraethylene glycol dimethyl ether, polyethylene glycol-350-dimethyl ether, polyethylene glycol-550-dimethyl ether, polyethylene glycol-750-dimethyl ether, where 350, 550 and 750 refer to the approximate average molecular weight of polyethylene glycol) and one or more antioxidants (such as butylated hydroxytoluene (BHT), butylated hydroxyanisole (BHA), propyl gallate, vitamin E, hydroquinone, hydroxycoumarin, ethanolamine, lecithin, cephalin, ascorbic acid, malic acid, sorbitol, phosphoric acid, thiodipropionic acid and its esters and dithiocarbamates).

[0180] Other formulations include, but are not limited to, aqueous alcoholic solutions containing pharmaceutically acceptable acetals. The alcohol used in these formulations is any pharmaceutically acceptable water-miscible solvent having one or more hydroxyl groups, including, but not limited to, propylene glycol and ethanol, at a concentration suitable for maintaining protein function. Acetals include, but are not limited to, di(lower alkyl) acetals of lower alkyl aldehydes, such as acetaldehyde diethyl acetal.

[0181] This article also covers parenteral administration via subcutaneous, intramuscular, or intravenous injection. Injectable formulations can be prepared in conventional forms, either as liquid solutions or suspensions, as solid forms suitable for dissolving or suspending in a liquid prior to injection, or as emulsions. Injectables, solutions, and emulsions also contain one or more excipients. Suitable excipients are, for example, water, saline, dextran, glycerol, or ethanol, at concentrations suitable for maintaining protein function. Furthermore, if desired, the pharmaceutical composition to be administered may contain small amounts of non-toxic excipients, such as wetting agents or emulsifiers, pH buffers, stabilizers, solubilizers, and other such agents, such as sodium acetate, sorbitol monolaurate, triethanolamine oleate, and cyclodextrin.

[0182] This document also considers implanting sustained-release or continuous-release systems to maintain a constant dose level (see, for example, U.S. Patent 3,710,795). In short, the compounds provided herein are dispersed in a solid internal matrix, such as polymethyl methacrylate, polybutyl methacrylate, plasticized or unplasticized polyvinyl chloride, plasticized nylon, plasticized polyethylene terephthalate, natural rubber, polyisoprene, polyisobutylene, polybutadiene, polyethylene, ethylene-vinyl acetate copolymer, silicone rubber, polydimethylsiloxane, organosilicon carbonate copolymer, hydrophilic polymers (such as hydrogels of esters of acrylic acid and methacrylate), collagen, crosslinked polyvinyl alcohol, and crosslinked partially hydrolyzed polyvinyl acetate. The matrix is ​​surrounded by an external polymer membrane insoluble in bodily fluids, such as polyethylene, polypropylene, ethylene / propylene copolymer, ethylene / ethyl acrylate copolymer, ethylene / vinyl acetate copolymer, silicone rubber, polydimethylsiloxane, chloroprene rubber, chlorinated polyethylene, polyvinyl chloride, copolymers of vinyl chloride and vinyl acetate, vinylidene chloride, ethylene and propylene, ionomer polyethylene terephthalate, butyl rubber, epichlorohydrin rubber, ethylene / vinyl alcohol copolymer, ethylene / vinyl acetate / vinyl alcohol terpolymer, and ethylene / ethyleneoxyethanol copolymer. The drug diffuses across the external polymer membrane during the release rate control step. The amount of drug contained in such parenteral compositions depends largely on the specific properties of the drug, the activity of the compound, and the needs of the subject.

[0183] Preparations intended for parenteral administration include sterile solutions prepared for injection, sterile dried soluble products (such as lyophilized powders) (including subcutaneous tablets) prepared for mixing with a solvent just before use, sterile suspensions prepared for injection, sterile dried insoluble products prepared for mixing with a solvent just before use, and sterile emulsions. Solutions may be aqueous or non-aqueous.

[0184] If administered intravenously, suitable carriers include physiological saline or phosphate-buffered saline (PBS), as well as solutions containing thickeners and solubilizers such as glucose, polyethylene glycol, and polypropylene glycol, and mixtures thereof.

[0185] Pharmaceutically acceptable carriers for parenteral preparations include aqueous solvents, non-aqueous solvents, antimicrobial agents, isotonic agents, buffers, antioxidants, local anesthetics, suspending and dispersing agents, emulsifiers, multivalent chelating agents or chelating agents, and other pharmaceutically acceptable substances.

[0186] Examples of aqueous parenteral solvents include sodium chloride injection, Ringer's solution, isotonic dextran injection, sterile water injection, dextran, and lactated Ringer's solution. Non-aqueous parenteral solvents include non-volatile plant-derived oils, cottonseed oil, corn oil, sesame oil, and peanut oil. Antimicrobial agents at antibacterial or antifungal concentrations can be added to parenteral preparations packaged in multi-dose containers. These antimicrobial agents include phenol or cresol, mercury, benzyl alcohol, chlorobutanol, methylparaben and propylparaben, thimerosal, benzalkonium chloride, and benzyl chloride. Isotonic agents include sodium chloride and dextran. Buffers include phosphates and citrates. Antioxidants include sodium bisulfate. Local anesthetics include procaine hydrochloride. Suspensions and dispersants include sodium carboxymethyl cellulose, hydroxypropyl methylcellulose, and polyvinylpyrrolidone. Emulsifiers include polysorbate 80 (TWEEN). ® 80). Multivalent chelating agents or chelating agents for metal ions include EDTA. Drug carriers also include: ethanol, polyethylene glycol, and propylene glycol for water-miscible solvents; and sodium hydroxide, hydrochloric acid, citric acid, or lactic acid for pH adjustment.

[0187] The concentration of the active pharmaceutical ingredient is adjusted so that the injection solution provides an effective amount sufficient to produce the desired pharmacological effect. As is known in the art, the exact dosage depends on the patient's or animal's age, weight, and condition.

[0188] Unit-dose parenteral preparations may be packaged in ampoules, vials, or syringes with needles. As is known and practiced in the art, all preparations for parenteral administration may be sterile.

[0189] Examplely, intravenous or intra-arterial infusion of a sterile aqueous solution containing the active compound is an effective route of administration. Another embodiment is a sterile aqueous or oily solution or suspension containing the active substance, which is injected as needed to produce the desired pharmacological effect.

[0190] The injectable formulation is designed for both local and systemic administration. In one embodiment, the therapeutically effective dose is formulated to achieve a concentration of the active compound in the treated tissue of at least about 0.1% w / w to about 90% w / w or higher (more than 1% w / w in some embodiments).

[0191] The medication can be suspended in a micronized or other suitable form. The form of the resulting mixture depends on many factors, including the intended route of administration and the solubility of the compound in the chosen carrier or solvent. An effective concentration sufficient to improve the symptoms of the condition can be determined empirically.

[0192] In other embodiments, the pharmaceutical formulation is a lyophilized powder that can be reconstituted for administration as a solution, emulsion, and other mixture. They can also be reconstituted and formulated as a solid or gel. Lyophilized powders are prepared by dissolving the pharmaceutical agents provided herein or their pharmaceutically acceptable derivatives in a suitable solvent. The lyophilized powder can be sterile. The solvent may contain excipients that improve the stability of the powder or a reconstituted solution prepared from the powder, or other pharmacological components. Excipients that can be used include, but are not limited to, dextran, sorbitol, fructose, corn syrup, xylitol, glycerol, glucose, sucrose, or other suitable pharmaceutical agents. The solvent may also contain a buffer, such as citrate, sodium phosphate, or potassium phosphate, or other such buffers known to those skilled in the art, with a pH approximately neutral. The solution is then sterilely filtered and lyophilized under standard conditions known to those skilled in the art to obtain the desired formulation. The resulting solution can be dispensed into vials for lyophilization. Each vial will contain a single or multiple doses of the compound. The lyophilized powder can be stored under suitable conditions, such as from about 4°C to room temperature.

[0193] Reconstitute the lyophilized powder with water for injection to provide a formulation for parenteral administration. For reconstitution, the lyophilized powder is added to sterile water or other suitable carrier. The precise amount depends on the compound selected. Such amounts can be determined empirically.

[0194] The topical mixture is prepared according to the methods described for both topical and systemic application. The resulting mixture may be a solution, suspension, emulsion, etc., and may be formulated into creams, gels, ointments, emulsions, solutions, elixirs, lotions, suspensions, tinctures, pastes, foams, aerosols, rinses, sprays, suppositories, bandages, transdermal patches, or any other formulation suitable for topical application.

[0195] The antibodies of the present invention can be formulated as aerosols for topical application, for example by inhalation (see, for example, U.S. Patents 4,044,126, 4,414,209, and 4,364,923, which describe aerosols for delivering steroids that can be used to treat inflammatory diseases, particularly asthma). These formulations for respiratory administration can be in the form of aerosols or nebulizer solutions, or in the form of ultrafine powders for inhalation, alone or in combination with an inert carrier such as lactose. In this case, in one embodiment, the particle diameter of the formulation will be less than 50 micrometers, and in another embodiment, the diameter is less than 10 micrometers.

[0196] The preparations can be formulated for topical or surface application, for example, for topical application to the skin and mucous membranes, such as in the eyes, in the form of gels, creams, and lotions, as well as for application to the eyes or for intracranial or intraspinal application. Topical application is intended for transdermal delivery, but also for application to the eyes or mucous membranes, or for inhalation therapy. Nasal solutions of the active compound alone or in combination with other pharmaceutically acceptable excipients can also be administered. These solutions (especially those for ophthalmic use) can be formulated as 0.01%–10% isotonic solutions with a pH of approximately 5–7 using appropriate saline solutions.

[0197] This article also considers other routes of administration, such as transdermal patches (including iontophoresis and electrophoresis devices) and rectal administration.

[0198] Transdermal patches (including iontophoresis and electrophoresis devices) are well known to those skilled in the art. For example, such patches are disclosed in U.S. Patents 6,267,983, 6,261,595, 6,256,533, 6,167,301, 6,024,975, 6,010,715, 5,985,317, 5,983,134, 5,948,433, and 5,860,957.

[0199] The pharmaceutical agents and other compositions provided herein can also be formulated to target specific tissues, receptors, or other regions of the body of a subject to be treated. Many such targeting methods are well known to those skilled in the art. All such targeting methods for use with the compositions of the present invention are contemplated herein. For non-limiting examples of targeting methods, see, for example, U.S. Patents 6,316,652, 6,274,552, 6,271,359, 6,253,872, 6,139,865, 6,131,570, 6,120,751, 6,071,495, 6,060,082, 6,048,736, 6,039,975, 6,004,534, 5,985,307, 5,972,366, 5,900,252, 5,840,674, 5,759,542, and 5,709,874. In some implementations, the agents described herein are targeted (or otherwise administered) to the brain, for example in patients who have Alzheimer's disease or are at risk of developing Alzheimer's disease.

[0200] In one aspect, the present invention provides a combination of an agent as defined in any of the preceding claims and other therapeutic components as defined herein.

[0201] Other therapeutic components include antibiotics and probiotics, such as those described herein. Exemplary probiotics include species of *Lactobacillus*, *Bifidobacterium*, *Saccharomyces boulardii*, *Streptococcus thermophilus*, *Enterococcus faecium*, and *Escherichia coli* Nissle 1917 (EcN). Other therapeutic components include molecules with anti-amyloid activity, such as BRICHOS domain proteins (SEQ ID NO: 4 or 5).

[0202] "Molecules with anti-amyloid activity" encompasses compounds or substances that exhibit the ability to inhibit or regulate the formation, aggregation, or toxicity of amyloid proteins. Molecules with anti-amyloid activity can target various stages of amyloid formation and aggregation, for example, by preventing misfolding and reducing the likelihood of misfolding into amyloid structures by stabilizing the native functional conformation of proteins; inhibiting aggregation by interfering with the aggregation process, specifically by preventing monomers from associating into oligomers or disrupting fibrillary growth; promoting depolymerization by promoting the breakdown of existing amyloid aggregates into smaller, less toxic substances, or by promoting their clearance through cellular mechanisms; and / or reducing toxicity by mitigating the toxic effects associated with amyloid aggregates, such as oxidative stress, inflammation, and neuronal dysfunction.

[0203] In one embodiment, the combination of the pharmaceutical agent and another therapeutic component is in a separate container and / or a separate composition. In another embodiment, the combination of the pharmaceutical agent and the other therapeutic component is formulated into a composition.

[0204] Separate compositions can be administered separately or simultaneously. Separate administration means that the two compositions are administered at different times, for example, at least 10 minutes, 20 minutes, 30 minutes, or 10-60 minutes apart, or at intervals of 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, or 12 hours. The compositions can also be administered at intervals of 24 hours or even longer. Alternatively, two or more compositions can be administered simultaneously, for example, at intervals of less than 10 minutes or less than 5 minutes. In some aspects, the simultaneously administered compositions can be administered as a mixture, each component having the same or different sustained-release mechanisms, or having no sustained-release mechanism.

[0205] The agent described herein can be conjugated or recombined with another therapeutic moiety (or one or more therapeutic moieties). The agent can be conjugated or recombined with a therapeutic moiety, such as another protein having anti-amyloid activity, for example, the BRICHOS domain (SEQ ID NO: 4 or 5).

[0206] Fusion proteins are hybrid proteins constructed by combining the coding sequences of two or more genes (typically from different sources) with the aim of producing a single polypeptide chain possessing properties derived from each component. Methods for generating fusion proteins are known in the art and include recombinant DNA techniques involving the in vitro manipulation of DNA sequences to construct fusion genes encoding the desired fusion protein. DNA sequences encoding the individual target proteins are linked together within a frame, enabling the production of a single mRNA transcript and a fusion protein with two domains. Techniques such as PCR amplification, restriction enzyme digestion, and DNA ligation are commonly used in recombinant DNA techniques to construct fusion genes. Gene synthesis techniques enable the custom synthesis of DNA sequences encoding fusion proteins without the need for pre-existing DNA templates. Researchers can design the desired fusion gene sequence, including appropriate linkers or spacers between the protein domains, and these sequences can be synthesized by commercial gene synthesis companies. Overlap extension PCR, also known as overlap extension splicing (SOE) PCR or PCR splicing, is a technique for amplifying DNA fragments with overlapping ends that can anneal together to form a fusion product. Primers are designed to amplify overlapping regions of two or more DNA fragments encoding the target protein domains. In subsequent PCR cycles, the overlapping regions anneal together, generating a fusion DNA fragment encoding the fusion protein. Fusion proteins can be produced in vivo using recombination techniques. For example, in yeast two-hybrid assays or other genetic screening systems, fusion proteins can be generated by fusing the coding sequences of two proteins into different regions of a reporter gene. The interaction between the two target proteins leads to the production of a functional reporter protein.

[0207] Ribosomal frameshifting is a natural mechanism that can be used to generate fusion proteins. By introducing programmed ribosomal frameshift sites between the coding sequences of two proteins, the ribosome can shift its reading frame during translation, thereby synthesizing a single polypeptide chain that simultaneously contains the domains of both proteins.

[0208] In one aspect, the present invention provides a pharmaceutical agent, pharmaceutical composition, use or method for use, substantially as described in the appended description, claims and examples.

[0209] The embodiments of the present invention will now be described with reference to the accompanying drawings, in which:

[0210] Figure 1Structure of Helicobacter pylori CagA and recombinant protein preparations. (a) Helicobacter pylori colonizes the human gastric mucosa and is associated with various human diseases, including gastrointestinal diseases, cardiovascular diseases, and neurodegenerative diseases such as AD and PD. (b) The CagA protein is a multifaceted molecule containing N-terminal and C-terminal regions. The C-terminal region is disordered, and the N-terminal region can be further subdivided into three distinct parts: domain I (D1), domain II (D2), and domain III (D3) (PDB ID4DVY). Domain I consists of 10 α-helices, domain II is characterized by substantially antiparallel β-sheets, including subdomains with five α-helices and two short β-sheets, while domain III adopts a four-helix bundle structure. (c and d) N-terminal region of CagA N The sample was expressed in *E. coli* and purified using IMAC, IEC, and SEC. Secondary structure was measured using circular dichroism (CD) spectroscopy, revealing an α-helical-dominant conformation. SDS-PAGE analysis confirmed high purity.

[0211] Figure 2. CagA N Inhibits biofilm formation and the assembly of functional amyloid. (a) Schematic diagram of bacterial functional amyloid and biofilm formation, where functional amyloid forms the structural framework of the biofilm. (b) CagA N Inhibits Pseudomonas biofilm formation. Pseudomonas species UK4 (wild-type and pFap species) were tested with and without recombinant CagA. N The protein was incubated and biofilm formation was assessed by Gram violet staining. For wild-type (WT) and pFap species, CagA... N A dose-dependent effect was observed in reducing biofilm formation. (c and d) Pseudomonas secretes FapC protein that assembles into amyloid fibrils. The effect was determined by ThT assay using 15 μM FapC and different concentrations of CagA ranging from 0 nM to 1280 nM. N The study of CagA N Inhibitory effect on FapC fibril formation. (e) Half-time (τ1 / 2) and maximum rate (rmax) were extracted by sigmoid fitting of the dataset in (e). (f and g) CsgA protein secreted by *E. coli* and assembled into amyloid fibrils. The inhibitory effect on FapC fibrils was determined by ThT assay using 15 μM FapC and different concentrations of CagA from 0 nM to 1280 nM. N The study of CagA N Inhibitory effect on CsgA fibril formation. (h) τ1 / 2 and rmax were extracted by sigmoid fitting of the dataset in (h).

[0212] Figure 3. CagA NPreventing the formation of amyloid by AD-related peptides and proteins. (a) Schematic diagram of pathogenic amyloid formation and some related human diseases. (b) Schematic diagram of amyloid formation and related peptides and proteins in AD. (c) Measurement by ThT using 3 μM Aβ42 and different concentrations of CagA from 0 nM to 50 nM. N Test CagA N Inhibitory effect on Aβ42 fibril formation. (d) τ1 / 2 and rmax were extracted by sigmoid fitting of the dataset in (c). (e and f) ThT determination was performed using 5 μM Aβ40 and different concentrations of CagA from 0 nM to 1 nM. N Test CagA N Inhibitory effect on Aβ40 fibril formation. (f) τ1 / 2 and rmax were extracted by sigmoid fitting of the dataset in (e). (g and h) ThT was used to determine the inhibitory effect of 15 μM tau and different concentrations of CagA from 0 nM to 500 nM. N Test CagA N Inhibitory effect on tau fibril formation. (h) τ1 / 2 and rmax were extracted by sigmoid fitting of the dataset in (g).

[0213] Figure 4. CagA N Inhibition of amyloid formation in PD and T2D-related proteins and peptides. (a) Schematic diagram of amyloid formation and related peptides and proteins in PD. (b) CagA assay by ThT measurement. N Inhibitory effect on the formation of 10 μM α-synuclein fibrils, while CagA N The concentration range was 0 μM to 3 μM. (c) Measured by ThT using CagA at concentrations from 0 μM to 0.5 μM. N Test CagA N Inhibitory effect on 30 μM α-synuclein fibrillation. (d) τ1 / 2 and rmax were extracted by sigmoid fitting of the dataset in (c). (e) ThT assay using CagA at concentrations from 0 μM to 1 μM. N Test CagA N Inhibition of 30 μM α-synuclein fibrillation at pH 5.5. (f) Extraction of τ1 / 2 and rmax by sigmoid fitting of the dataset in (e). (g) Schematic diagram of amyloid formation and related peptide IAPP in T2D. (h) Determination of ThT using CagA at concentrations from 0 μM to 0.1 μM. N Test CagA N Inhibitory effect on the formation of 10 μM IAPP fibrils. (i) τ1 / 2 and rmax were extracted by sigmoid fitting of the dataset in (h).

[0214] Figure 5 .CagA N Different microscopic events interfere with the formation of fibrils from various amyloid peptides or proteins. The dynamics of amyloid aggregation involve different stages. 29 In the primary nucleation stage, monomers aggregate to form nuclei (primary nucleation, kn), from which the protofibrils can begin to extend (extension, k+). Simultaneously, during secondary nucleation (k2), monomers adhere to the protofibril surface, catalyzing the formation of new nuclei and promoting exponential growth of the protofibrils. See the diagrams in (a) and (b) for a visual understanding of this process. (a) CagA N It inhibits the formation of amyloid substances from different bacterial functional amyloid proteins (i.e., CsgA from Escherichia coli and FapC from Pseudomonas). For these amyloid-forming proteins, CagA... N The main obstacle to the extension process is indicated by the cross. (b) CagA N CagA inhibits the formation of amyloid fibrils from various human pathogenic amyloid peptides or proteins through different mechanisms. Regarding the AD-associated Aβ42 and Aβ40 peptides, primary nucleation is primarily blocked. Conversely, for the AD-associated protein tau, both secondary nucleation and elongation are inhibited by CagA. N The impact. Regarding the PD-related protein α-synuclein, CagA N Inhibits the elongation process. Fibrosis of IAPP peptides associated with T2D is inhibited by CagA. N Suppression affects secondary nucleation and elongation processes. Details of the global fit for each dataset are included in... Figures 7 to 9 middle.

[0215] Figure 6. CagA N Interactions with amyloid-forming substrates. (a) CagA N (Red spectrum) and no CagA N (b) NMR spectrum of 15N-labeled α-synuclein (blue spectrum). (c) With and without CagA N The relative intensity of each amino acid in the α-synuclein. Residues marked with an asterisk (*) were excluded from the analysis due to their low signal-to-noise ratio. (c and d) CagA N SPR analysis of α-synuclein oligomers or fibrils. (e) CagA N (f) SPR analysis of CagA and Aβ42 monomers. (g) ZDOCK analysis of the interaction between CagA and Aβ42 monomers. (h) Cartoon diagram of the D2 domain, with hydrophobic amino acid residues shown in a rod-like model. (f) ThT assay of CagA at concentrations from 0 nM to 100 nM. N Test CagA NThe D2 domain inhibits the formation of 3 μM Aβ42 protofibrils. (i) τ1 / 2 and rmax are extracted by sigmoid fitting of the dataset in (h). (j) CagA N The D2 domain inhibits the formation of amyloid fibrils from the Aβ42 peptide by suppressing primary nucleation.

[0216] Figure 7 In different CagA N Aggregation kinetics of FapC and CsgA in the presence of different CagA concentrations. N The aggregation kinetics of 15 μM FapC (a) or CsgA (b) at the presence of certain concentrations are shown in the labels on the right side of the subplot. The global fit (solid line) of the aggregation trajectory (points) is constrained such that only a single rate constant (i.e., kn, k2, or k+) is the only free fitting parameter. A checkmark indicates a satisfactory fit, while a cross indicates an unsatisfactory fit.

[0217] Figure 8. Different CagA N Aggregation kinetics of Aβ42, Aβ40, and tau in the presence of different CagA concentrations. N The aggregation kinetics at concentrations of 3 μM Aβ42 (a), 5 μM Aβ40 (b), or 15 μM tau (c) are shown as labeled on the right side of the subplot. The global fit (solid line) of the aggregation trajectory (points) is constrained such that only a single rate constant (i.e., kn, k2, or k+) is the only free fitting parameter. A checkmark indicates a satisfactory fit, while a cross indicates an unsatisfactory fit.

[0218] Figure 9 In different CagA N Aggregation kinetics of α-synuclein and IAPP in the presence of different CagA concentrations. N The aggregation kinetics of 30 μM α-synuclein (α-syn) (a) or 10 μM IAPP (b) at the present concentrations are shown in the labels on the right side of the subplot. The global fit (solid line) of the aggregation trajectory (points) is constrained such that only a single rate constant (i.e., kn, k2, or k+) is the only free fitting parameter. A checkmark indicates a satisfactory fit, while a cross indicates an unsatisfactory fit.

[0219] Figure 10. α-synuclein monomers and CagA by FIDA. N Interaction measurements were performed. α-synuclein monomers were labeled with ALC480 and used as indicators, while CagA... NThe analyte was ALC480-labeled α-synuclein monomer, yielding a hydrodynamic radius (Rh) of 2.9 nm, indicating its inherent disordered nature. (b) Analysis was performed with and without very large excesses of CagA. N In the case of analysis of ALC480-labeled α-synuclein monomers, the difference in rh values ​​was small, indicating that α-synuclein and protein CagA... N There is no strong interaction between them.

[0220] Figure 11. Aβ42 and CagA N Co-incubation. (a) Analysis by SDS-PAGE of different concentrations of CagA in the presence and absence of CagA. N (b) Analysis of 3 μM Aβ42 incubated with and without 5 μM CagA by native-PAGE. N (c) 5 μM Aβ42 was incubated under these conditions. (c) Analysis by mass spectrometry with CagA N The mass of Aβ42 after co-incubation.

[0221] Figure 12 Recombinant CagA N Preparation of the D2 domain. (a) Purified recombinant CagA N SDS-PAGE analysis of the D2 domain. (b) Recombinant CagA N CD measurement of the D2 structural domain.

[0222] Figure 13. Different CagA N The aggregation kinetics of α-synuclein and Aβ42 in the presence of D2 concentration. (The last part, "different CagA...", appears to be incomplete and unrelated to the preceding text. It has been left as is.) N The aggregation kinetics of 30 μM α-synuclein (α-syn) (a) or 3 μM Aβ42 (b) at the present concentrations are shown in the labels on the right side of the subplot. The global fit (solid line) of the aggregation trajectory (points) is constrained such that only a single rate constant (i.e., kn, k2, or k+) is the only free fitting parameter. A checkmark indicates a satisfactory fit, while a cross indicates an unsatisfactory fit. Example

[0223] Example 1 - Helicobacter pylori releases strong anti-amyloid protein molecules

[0224] Bacteria, the smallest and most abundant life forms on Earth, offer profound insights and strategies for humankind, significantly impacting science and technology. From the development of crucial antibiotics to groundbreaking gene-editing technologies, bacteria have proven to be a treasure trove of inspiration. Here, we discover that bacteria can release highly effective molecules to inhibit the formation of functional and pathogenic amyloid fibrils, fibrous protein assemblies associated with bacterial biofilm formation and various human diseases. The broad anti-amyloid substrate profile of the CagA (cytotoxin-associated gene A) protein secreted by Helicobacter pylori reveals the mechanisms by which these bacteria interfere with other bacteria and humans, holding promise for drug interventions aimed at combating bacterial infections and human protein misfolding diseases. Our findings highlight the profound inspiration the microbial world provides for numerous areas of human innovation and scientific exploration.

[0225] introduce

[0226] Bacteria are often underestimated due to their microscopic size, but they possess a wealth of ingenious strategies that span numerous scientific and technological fields. From the development of life-saving antibiotics stemming from the "war" between microorganisms... 1 From gene editing technology, inspired by the precision of bacterial defense systems, to... 2 Even the development of specialized protein injectors that mimic bacterial appendages. 3 These tiny life forms provide a rich source of innovation. They offer insights into gene manipulation, with potential applications in health, agriculture, and personalized medicine. This microbial realm continues to demonstrate its boundless wisdom, providing profound inspiration for humanity in many areas of innovation and exploration. Amyloid is a highly ordered assembly of protein fibers (nanofibers) that can be functional or pathogenic. 4 In recent decades, extensive characterization has revealed the highly organized nature of amyloid nanofibrils with a diameter of approximately 10 nm, characterized by an unbranched structure and well-defined β-sheets oriented perpendicular to the fibril axis. 5 Natural amyloids exhibit non-pathological functions and have clearly defined physiological effects. 6 It is ubiquitous in various natural species, including humans (e.g., p-mel and certain polypeptide hormones). 4 and invertebrates (e.g., insects) 7 and spiders 8、9 It is worth noting that bacteria also enrich this functional amyloid protein profile by secreting amyloid substances, including *Escherichia coli* and various *FapC* species, all of which are common members of the human gut microbiota. 10Bacterial amyloid fibrils play a crucial role in maintaining the structural integrity of biofilms, enabling bacteria to adhere to surfaces and other bacterial cells, retain nutrients and water, and also act as a protective barrier. Biofilm-associated pathogens are protected from antimicrobial agents and the host immune system, making them more infectious and difficult to treat effectively. In fact, 80% of all chronic infections are related to bacterial biofilms. 11 When amyloid-forming proteins mutate or amyloid formation is inhibited, biofilms are disrupted and bacteria become more susceptible to environmental factors. 11 On the other hand, pathogenic amyloids represent a class of pathogenic protein aggregates characterized by their distinctive fibrous structure and insolubility, and are intricately associated with a broad spectrum of incurable debilitating diseases known as amyloidosis, including Alzheimer's disease (AD), Parkinson's disease (PD), and type 2 diabetes (T2D). 5、12 Each condition is characterized by the deposition of specific amyloid-forming peptides or proteins, exhibiting different pathogenicities and associated clinical manifestations of amyloid aggregates. 4 Inspired by the antibiotic-producing ability of some bacteria and the importance of amyloid formation in bacterial biology, it is conceivable that certain bacterial species may have evolved mechanisms to inhibit amyloid formation, ultimately affecting the growth of neighboring bacterial communities.

[0227] Helicobacter pylori is a ubiquitous Gram-negative bacterium that can colonize the human gastric mucosa, affecting approximately 50% of the global population. 13 Due to its crucial role in triggering a range of gastrointestinal diseases, including gastric ulcers, this microbe has attracted widespread attention in the medical and scientific fields. Furthermore, it has raised intriguing possibilities for an increased susceptibility to cardiovascular diseases and neurodegenerative diseases, including PD and AD. 14 Although the exact mechanisms remain unclear, Helicobacter pylori is also known for its ability to alter the microbiota of the stomach and intestinal regions, leading to a variety of diseases and affecting the production and physiological regulation of intestinal metabolic hormones. 15、16 Based on the presence or absence of the cagA gene, Helicobacter pylori strains can be divided into cagA (cytotoxin-associated gene A) positive and cagA negative types. Interestingly, cagA-positive Helicobacter pylori strains can induce changes in gut microbiota diversity and abundance. 15、17、18 CagA also interferes with the production of antimicrobial peptides in the gut. 19 and activate the host's immune response. 17 Both of these can further alter the composition and diversity of the gut microbiota. CagA expression in Drosophila intestinal stem cells is sufficient to alter the host microbiota. 20Although there is increasing research on the effects of CagA protein on the gut microbiota, the exact mechanisms by which it alters the gut microbiota are not yet fully understood.

[0228] These observations collectively lead to the hypothesis that bacteria in the natural environment may have evolved mechanisms to regulate amyloid formation, potentially influencing the growth and behavior of other bacteria residing within biofilms and / or those associated with human protein misfolding diseases. Surprisingly, in this study, we discovered that Helicobacter pylori CagA is a highly effective anti-amyloid molecule with a broad substrate spectrum, revealing a mechanism by which Helicobacter pylori interferes with other bacteria and humans, demonstrating pharmaceutical potential in intervening in bacterial infections and human protein misfolding diseases.

[0229] CagA inhibits biofilm formation and the assembly of functional amyloid compounds.

[0230] CagA protein is a virulence factor secreted by Helicobacter pylori. It is delivered to the host cell cytoplasm via a complex type IV secretion system, and has been detected in the blood of infected patients at concentrations in the micromolar range. 21 CagA consists of multiple structural domains / regions: an N-terminal structured region and a disordered C-terminal tail used to interfere with host signal transduction. Figure 1 a and Figure 1 b) 22、23 Due to structural polymorphism in the C-terminal region, the size of the CagA protein ranges from 130 kDa to 145 kDa. 22 Notably, the N-terminal region is considered to act as a repressive domain that inhibits the function of the C-terminal region, and when expressed independently, the region spanning amino acid 800-1216 induces the highest degree of epithelial cell elongation. 24 Furthermore, CagA undergoes protease cleavage in human cells, producing two fragments of approximately 100 kDa to 105 kDa and 35 kDa to 40 kDa, the latter corresponding to the amino acid 800-1216 region containing the EPIYA segment. 25 Therefore, this study focuses on the N-terminal region from position 1 to 884, named CagA. N It can be divided into three domains: domain I, domain II, and domain III. Domain I contains 10 α-helices, domain II has a large antiparallel β-fold and contains a subdomain with five α-helices and two short β-folds, and domain III adopts a four-helix bundle structure, with its C-terminal region derived from a long α-helix connecting domains II and III. Figure 1 b) 23、26 CagA NThe recombinant CagA was expressed in *E. coli* and subsequently purified using immobilized metal affinity chromatography (IMAC), ion exchange chromatography (IEC), and size exclusion chromatography (SEC). N It exhibits a conformation dominated by α-helices and has high purity. Figure 1 c and Figure 1 d), which is highly consistent with the crystal structure of the N-terminal portion (PDB ID 4DVY) ( Figure 1 b).

[0231] Bacteria commonly found in the human gut microbiome (such as Escherichia coli and several species of Pseudomonas (FapC)) have the ability to produce amyloid substances. 10 These functional amyloid fibrils are crucial for maintaining the structural stability of biofilms—densely packed microbial communities—and for establishing protective barriers (Figure 2a). 27 This barrier presents a challenge in combating biofilm-associated pathogens, making them less susceptible to microbial agents and complicating effective microbial treatments. 11 Mutations that disrupt amyloid-forming proteins or inhibit amyloid formation can lead to biofilm breakdown, making bacteria more vulnerable to environmental influences. To evaluate CagA... N To investigate its potential in preventing biofilm formation, we examined its effects on *Pseudomonas* species, including both wild-type and pFapC protein variants (Figure 2b). Surprisingly, CagA... N The study showed effective concentration-dependent inhibition of biofilm formation in both wild-type Pseudomonas and pFapC species (Figure 2b). This observation raises an interesting possibility regarding the mechanism behind the ability of CagA-positive Helicobacter pylori strains to induce changes in gut microbiota diversity and abundance, suggesting that Helicobacter pylori may have the ability to inhibit biofilm formation in different bacterial species.

[0232] To further understand whether the anti-biofilm effect stems from the inhibition of functional amyloid formation, considering that amyloid is essential for stabilizing biofilm structure, we evaluated CagA. N Two common protein components (FapC from Pseudomonas and CsgA from Escherichia coli (Figs. 2c, 2d, 2f, and 2g)) are prevalent in the human gut microbiome. 10 The effectiveness of this assay in amyloid fibril formation was evaluated using thioflavin T (ThT) fluorescence assays, where ThT is a dye specifically designed to bind to amyloid structures and induce an increase in fluorescence intensity. 28 Surprisingly, CagA NIt exhibits excellent efficacy against amyloid formation, showing significant inhibitory effects at nanomolar concentrations in tests against 15 μM FapC or CsgA. This is demonstrated by parameters such as half-time (τ). 1 / 2 ) and maximum rate (r max Quantitative analysis was performed using parameters such as (Figures 2d, 2e, 2g, and 2h) to recombinant CagA. N The concentration-dependent effects on FapC and CsgA were significant. When using 1.3 μM CagA... N When antagonizing a 15 μM amyloid-forming substrate, the τ of FapC 1 / 2 The time was extended from approximately 3 hours to 16 hours, while CsgA's τ 1 / 2 The increase in time from approximately 2 hours to 32 hours (Fig. 2e and Fig. 2h) indicates that Helicobacter pylori CagA is a highly effective candidate for inhibiting the formation of functional bacterial amyloid fibrils. These results reveal a potential mechanism by which Helicobacter pylori alters the growth of neighboring bacterial communities by modifying biofilm integrity.

[0233] CagA effectively inhibits the formation of pathogenic amyloid.

[0234] CagA is remarkably effective in inhibiting the formation of functional amyloids, prompting us to investigate whether the anti-amyloid properties of CagA can be extended to pathogenic amyloid-forming peptides or proteins. These pathogenic amyloids are closely associated with human diseases such as AD, PD, and T2D (Figure 3a), specifically with amyloid β protein (Aβ, including subtypes Aβ42 and Aβ40), tau, α-synuclein, and islet amyloid peptide (IAPP), respectively. 5、12 Initially, we evaluated CagA using ThT fluorescence assays. N The efficacy of CagA against pathogenic amyloid-forming peptides and proteins associated with Alzheimer's disease—particularly Aβ42, Aβ40, and tau (Figure 3b), which were produced and purified in *E. coli*. Surprisingly, CagA… N It exhibited excellent efficacy, showing a significant inhibitory effect at nanomolar concentrations when tested for the formation of 3 μM Aβ42 fibrils (Figure 3c). Quantitative analysis highlighted the efficacy of recombinant CagA. N Concentration-dependent effect on Aβ42 (Figure 3d). When only 50 nM CagA was used... N At that time, τ 1 / 2 The treatment duration was extended from approximately 1.5 hours to 21 hours to prevent the formation of fibrils by 3 μM Aβ42. It is noteworthy that r max No significant changes were observed (Fig. 3d). Interestingly, the efficacy against Aβ42 protofibrillation also extended to the Aβ40 peptide (Fig. 3e and Fig. 3f), and 1nMCagA NThis is sufficient to delay fibril formation with 5 μM Aβ40 from approximately 14 hours to 19 hours, and r max No significant changes were observed (Figures 3e and 3f), indicating that CagA is a potent inhibitor of Aβ fibril formation. Extending our research beyond shorter Aβ peptides, we explored the effects of CagA... N The activity of tau protein, a large, positively charged amyloid-forming protein associated with AD, was examined. A detailed examination of fibrillation in recombinant tau protein purified from *E. coli* was performed using ThT fluorescence assays (Fig. 3g and Fig. 3h). Similar to its effect on Aβ peptides, CagA... N The effect on tau amyloid fibrillation showed a concentration-dependent delay in fibrillation, with a significant effect observed at 10 nM when 15 μM tau was applied (Fig. 3g and Fig. 3h). Notably, the use of 500 nM CagA... N When 15 μM tau is inhibited from forming fibrils, τ 1 / 2 The duration increased from approximately 38 hours to 81 hours. These results indicate that CagA... N It is an amyloid formation inhibitor that is effective against substrates of different sizes and charges.

[0235] To evaluate CagA N Exhibiting broad anti-amyloid activity, we further investigated its effectiveness against α-synuclein, a protein known to form fibrils and aggregate into Lewy bodies, a key histological finding in PD (Figure 4a). Using α-synuclein produced and purified from *E. coli*, we evaluated CagA using ThT fluorescence assay. N The efficacy against this PD-associated amyloid-forming protein is consistent with its anti-amyloid formation effects in other protein systems (Figures 2 and 3). CagA N It also showed excellent efficacy against α-synuclein; complete inhibition was observed at nanomolar concentrations when tested against 10 μM α-synuclein (Figure 4b). For example, 100 nM CagA N The formation of fibrils from 10 μM α-synuclein was completely prevented. Subsequently, we increased the α-synuclein concentration to 30 μM and used different concentrations of CagA... N (Figure 4c), at this time, CagA is recombined. N The concentration-dependent effect on α-synuclein became apparent. Quantitative analysis, including the parameter τ, was performed. 1 / 2 and r max (Figure 4d) highlights CagA N Concentration-dependent effects on α-synuclein. Using 500 nM CagA N τ1 / 2 Extending the treatment time from approximately 20 hours to 65 hours effectively inhibited the formation of fibrils from 30 μM α-synuclein (Figure 4d). Notably, CagA... N The anti-amyloid activity of α-synuclein persists even under acidic conditions. At pH 5.5, CagA... N It exhibited a concentration-dependent effect, preventing the formation of fibrils from 30 μM α-synuclein (Figure 4e). Using 1 μM CagA... N τ 1 / 2 The duration of CagA's activity increased from approximately 10 hours to 35 hours, demonstrating its significant efficacy in inhibiting the formation of fibrils from 30 μM α-synuclein at acidic pH (Figure 4f). This indicates that CagA can tolerate different pH levels without compromising its anti-amyloid activity.

[0236] Continue exploring CagA N To investigate the effectiveness against amyloid formation, we studied another human disease—T2D—in which the peptide hormone IAPP produced by pancreatic β-cells forms amyloid fibrils (Fig. 4g). Using IAPP produced and purified from *E. coli*, we evaluated CagA using a ThT fluorescence assay. N The effect on this amyloid-forming peptide. It is worth noting that CagA... N It also showed excellent efficacy against IAPP, exhibiting significant inhibition at nanomolar concentrations in tests against 10 μM IAPP (Figure 4h). To further illustrate its efficacy, 100 nM CagA... N It hindered the formation of fibrils by 10μM IAPP, reducing the half-time τ 1 / 2 The duration increased from approximately 0.3 hours to 1.7 hours, while r max Decrease (Figure 4i). Parameter τ 1 / 2 and r max The examination (Figure 4i) helps to gain a deeper understanding of recombinant CagA. N The concentration-dependent effect of IAPP. This indicates that CagA N Its efficacy in preventing IAPP from forming fibrils further underscores its potential as a therapeutic candidate for addressing T2D-associated amyloid pathology.

[0237] In summary, these findings demonstrate that CagA protein secreted by Helicobacter pylori possesses outstanding efficacy as an anti-amyloid molecule, exhibiting a broad substrate spectrum associated with various biological functions. This observation suggests that the anti-amyloid properties of CagA secreted by Helicobacter pylori are specific, differing from typical molecular chaperone functions.

[0238] Different mechanisms by which CagA inhibits amyloid formation

[0239] Amyloid aggregation kinetics involves several microscopic processes. 29、30 In the primary nucleation stage, monomers aggregate to form nuclei (primary nucleation, k n The protofibril can eventually evolve from this nucleus and begin to extend (extension, k) + Simultaneously, during secondary nucleation (K2), monomers adhere to the protofibril surface, catalyzing the formation of new nuclei and promoting exponential protofibril growth. Various proteins (such as molecular chaperones) 31 This can influence various microscopic events. Furthermore, even a single mutation in a given protein can alter its effect on nucleation events. This highlights the complex nature of the interaction between protein dynamics and amyloid formation. 32、33 To evaluate CagA N To investigate the effects of different amyloid-forming substrates on amyloid fibril formation and to determine their influence on specific micro-processes, we conducted a comprehensive analysis using global fitting of a kinetic dataset. Experiments involved maintaining constant concentrations of amyloid peptides or proteins while varying CagA levels. N The concentration. During this global fitting process, using the integral rate law, we impose constraints such that only a single rate constant—k—is allowed. n k2 or k + —As the sole fitting parameter variation. This method allows us to isolate and carefully examine the individual contributions of these micro-processes, revealing the CagA... N The interaction between and amyloid fibril formation kinetics.

[0240] Kinetic analysis revealed that CagA N It has multifaceted effects on the formation of amyloid fibrils in bacterial functional amyloid proteins and human pathogenic amyloid peptides / proteins. In the case of bacterial functional amyloid proteins, namely CsgA from *Escherichia coli* and FapC from *Pseudomonas*, CagA… N It exhibits a significant inhibitory effect. It primarily hinders elongation (k... + The process inhibits the formation of amyloid structures. Figure 5 a, Figure 7 a and Figure 7 b). Turning to human pathogenic amyloid peptides and proteins, CagA N The impact varies across different entities. In the context of AD, CagA... N It selectively targets specific processes. For AD-related Aβ42 and Aβ40 peptides, primary nucleation is the main target of inhibition. Figure 5 b, Figures 8a and 8b). Conversely, in the case of the AD-associated protein tau, CagA... N Influences secondary nucleation and elongation processes ( Figure 5b, Figure 8c). For the PD-related protein α-synuclein, CagA N It specifically inhibits the elongation process, exhibiting a unique interference pattern. Figure 5 b、 Figure 9 a). Furthermore, in the case of IAPP related to T2D, CagA N It exhibits a significant inhibitory effect on both secondary nucleation and elongation processes. Figure 5 b、 Figure 9 b). These findings collectively highlight CagA N Different ways in which a range of amyloid-producing proteins and peptides regulate the complex process of amyloid fibril formation.

[0241] To clarify CagA N Given the complex molecular interactions between various amyloid-forming peptides and proteins, we focused on α-synuclein and Aβ42. We first employed flow-induced dispersion analysis (FIDA) to investigate CagA... N Potential interactions with monomeric α-synuclein. Here, ALC480-labeled monomeric α-synuclein serves as an indicator, CagA N As an analyte. Notably, we observed monomeric α-synuclein with CagA. N There was no significant interaction between them. However, in large amounts of excess CagA... N A slight increase in size was detected in the presence of [the substance] (Figure 10), indicating the presence of minimal interactions. Furthermore, we recorded [the interaction] using nuclear magnetic resonance (NMR) spectroscopy. 15 N-labeled α-synuclein monomers and unlabeled CagA N 2D 1 H- 15 N HSQC experiment. By comparing the overlapping spectra, there was no decrease in cross-peak signal intensity corresponding to the relative intensity of each amino acid residue or any change in chemical shift, proving that only CagA was detected. N The small interactions between CagA and α-synuclein monomers (Fig. 6a and Fig. 6b). Conversely, surface plasmon resonance (SPR) analysis indicates that CagA... N The strong binding affinity between it and α-synuclein oligomers, the binding affinity (K... D The value is approximately 95 nM (Figure 6c). Furthermore, CagA... N K exhibits high affinity for α-synuclein fibrils. D The molecular weight is approximately 58 nM (Fig. 6d), indicating that it can selectively inhibit the formation of α-synuclein fibrils. The binding kinetics differ for the Aβ42 peptide. CagA N Nanomoore affinity (K) D=approximately 77 nM) bound monomer form (Fig. 6e), but SPR showed no detectable binding with Aβ42 fibrils. This indicates that CagA N The preferential binding to Aβ42 monomers highlights its potential regulatory role in Aβ42 aggregation. Figure 5 The global fitting analysis in b is consistent. Furthermore, CagA... N After co-incubation with Aβ42, SDS-PAGE and native-PAGE analyses confirmed that CagA N It exhibits concentration-dependent regulatory effects, promoting the stability of Aβ42 monomers (Figures 11a and 11b). As confirmed by mass spectrometry, these monomers remain intact in the residue sequence (Figure 11c). In summary, these findings elucidate the role of CagA... N It disrupts the different stages of amyloid formation in a wide range of amyloid-forming peptides and proteins, thereby preventing their aggregation into amyloid fibrils through different mechanisms.

[0242] The important role of the CagA D2 domain in inhibiting amyloid activity

[0243] CagA consists of different structural domains and regions, possessing a structured N-terminus and a disordered C-terminal tail. The N-terminus can be further divided into three structural domains: domains I, II, and III, each with different structures. 22、23 ( Figure 1 b). N-terminal domain I interacts with the tumor suppressor; domains II and / or III are important for delivery into the host cell and subsequent membrane localization. 22、23 Domain II possesses a charged K-Xn-RXR motif located within the α-helix, which can bind phosphatidylserine. 22 CagA's modular organization highlights its complex structural architecture, where different regions contribute to its overall function. To determine the active domains responsible for CagA's anti-amyloid activity, we used the ZDOCK procedure. 34 The interaction between CagA and the Aβ42 monomer was simulated. Notably, the Aβ42 monomer is coupled to the β-zigzag structure of domain II (Fig. 6f), characterized by exposed hydrophobic patches (Fig. 6g). To further evaluate the activity of domain II, this domain was recombinantly expressed in E. coli, followed by purification. Figure 12 a, Figure 6j), CD measurements indicate that it was folded correctly ( Figure 12 b). Interestingly, domain II exhibits potent anti-Aβ42 activity, preventing the formation of amyloid fibrils (Fig. 6h). In the presence of 100 nM domain II, τ 1 / 2 The duration has been extended from approximately 1.5 hours to 12.5 hours (Figure 6i). maxIt showed a slightly linear decrease with increasing concentration of domain II (Figure 6i). Kinetic analysis revealed that, compared with CagA... N Similarly, domain II primarily inhibits primary nucleation of Aβ42 protofibrils (Figure 13), and its mechanism is similar to that of CagA. N The mechanism of resistance to Aβ42 is the same ( Figure 5 b), Figure 8a), shows that D2 is an important domain in CagA with anti-amyloid activity.

[0244] Discussion

[0245] In this study, we discovered that certain bacterial species have evolved the ability to significantly inhibit amyloid and biofilm formation, profoundly impacting the growth of neighboring bacterial colonies. This phenomenon may constitute a key natural basis for potential applications in antibiotic production and gene editing strategies. The discovery of the Helicobacter pylori CagA protein as an anti-amyloid molecule not only reveals the regulation of amyloid dynamics by microorganisms but also proposes a new intersection between microbial interactions and human diseases. The dual role of Helicobacter pylori, particularly its influence on other bacterial populations and its impact on human protein misfolding diseases, reveals a complex network of biological interactions. These insights offer new prospects for leveraging microbial products to advance drug development, especially in the areas of bacterial infection management and the treatment of protein misfolding diseases. Thus, bacteria continue to emerge as a reservoir of biological innovation, proposing strategies that can drive progress across various scientific disciplines, from novel medical therapies to revealing complex biological interactions within the human body.

[0246] Bacterial infections, manifesting in both acute and chronic forms, significantly impact human health. Notably, the pathogenic activity of Helicobacter pylori underscores the importance of understanding the pathophysiology, transmission dynamics, and clinical management of bacterial infections for global health, influencing prevention and treatment strategies. This article demonstrates the superior efficacy of the Helicobacter pylori CagA protein in inhibiting amyloid formation, suggesting that Helicobacter pylori may contribute to human pathology through a unique mechanism.

[0247] The gut microbiota is crucial for normal physiology and disease susceptibility, exhibits tremendous diversity, and can be influenced by host-specific factors such as infection. 36 These factors can cause a variety of health outcomes, including gastrointestinal and nervous system disorders. 37 CagA-positive Helicobacter pylori strains have been shown to alter the diversity and abundance of the gut microbiota. 15、17、18 However, the impact of CagA-negative strains remains to be fully elucidated. Furthermore, the association between Helicobacter pylori infection, particularly CagA-positive strains, and neurodegenerative diseases such as Alzheimer's disease involves multiple potential mechanisms, including bacterial entry into the brain via the oral-nasal-olfactory route or through infected circulating mononuclear cells.38 Nevertheless, conflicting results from different studies regarding the link between Helicobacter pylori and Alzheimer's disease (AD) may be due to varying prevalences of CagA-positive Helicobacter pylori infection, necessitating further large-scale randomized controlled trials to clarify this relationship. 38 For example, in Japan, most strains are CagA positive, but no significant difference in the prevalence of Helicobacter pylori infection was found between AD patients and controls. 39、40 Interestingly, mice infected with Helicobacter pylori exhibited severe gastritis and increased neuroinflammation, but did not show cerebral amyloid deposition or systemic inflammation. 41 While the exact relationship between Helicobacter pylori infection and Alzheimer's disease (AD) remains uncertain, it is noteworthy that the prevalence of CagA-positive Helicobacter pylori infection varies by region. In Western countries, approximately 30% to 40% of Helicobacter pylori strains are cagA-negative, while almost all strains isolated from East Asian countries are cagA-positive. 40 CagA's potent anti-amyloid activity provides a mechanistic explanation: CagA can block the formation of the biofilm scaffold—functional amyloid material—thus making neighboring bacteria more susceptible to the microenvironment. On the other hand, amyloid fibrils exhibit compelling structural similarities to viral fusion domains and antimicrobial peptides, as well as sequence similarities to specific bacterial bacteriocin families. 43 The highly potent anti-amyloid activity of CagA may explain its underlying mechanism: it binds to antimicrobial peptides with similar structures to amyloid, thus inhibiting their antibacterial activity. Understanding the molecular mechanisms of the interaction between Helicobacter pylori and the CagA protein will provide valuable insights into the pathogenesis of diseases associated with this bacterium and may pave the way for new therapeutic strategies. Functional amyloids can enhance biofilms, posing a significant threat to human health because chronic infections they cause are difficult to treat due to the structural integrity of the biofilm and insufficient drug penetration, thus promoting antibiotic resistance. Targeting biofilms and their amyloid components with highly potent anti-amyloid molecules may be a novel approach to combat antibiotic resistance and induce changes in gut microbiota diversity and abundance.

[0248] Proteins are essential for countless biological functions and must maintain a precise three-dimensional conformation to function effectively. However, proteins have an inherent tendency to deviate from their native state, forming aggregates that can manifest as non-fibrous amorphous aggregates or fibrous amyloid structures. 44 Non-fibrous amorphous aggregates are associated with a range of diseases, including cancer and cataracts. 4 Furthermore, fibrous amyloid structures exhibit neurotoxicity and are associated with approximately 40 human diseases, particularly neurodegenerative diseases such as AD and PD, as well as systemic conditions such as T2D. 44Molecular chaperones play a crucial role in protein homeostasis networks, promoting correct folding and preventing abnormal aggregation. However, an age-related decline in the efficiency of protein homeostasis networks is associated with an increased prevalence of protein misfolding diseases in older adults. 45、46 Recent advances in monoclonal antibody drugs targeting Aβ have shown promise in the treatment of Alzheimer's disease (AD), supporting the use of amyloid-targeting approaches as an effective strategy for AD treatment. 47 Experimental data indicate that molecular chaperones can prevent protein aggregation in neurodegenerative diseases, including Alzheimer's disease, both in vitro and in vivo. 48 For example, the BRICHOS domain has been shown to have preventive and therapeutic effects on amyloid fibrillation and toxicity in AD models. 49 Comprehensive interventions targeting multiple aspects of Alzheimer's disease (including tau pathology, neuroinflammation, and oxidative stress) are increasingly considered necessary. 50 The challenges of protein misfolding diseases, exemplified by Alzheimer's disease (AD), the most common form of dementia, highlight the necessity of innovative research methods due to the high failure rate of clinical trials. CagA protein, unlike molecular chaperones, represents a novel bacterial protein with significant anti-amyloid activity and a broad substrate spectrum. Future research should focus on translating this activity into therapeutic applications for human protein misfolding diseases, particularly targeting subdomains.

[0249] method

[0250] Preparation of recombinant CagA-related protein

[0251] The recombinant N-terminal region of the CagA protein from Helicobacter pylori, starting from position 1-884 (named CagA), was selected. N ), and domain II (D2, with NT* solubilizing tag) 51 (The text abruptly shifts to a different topic) The cells were expressed separately in *E. coli* BL21(DE3) cells. Cells were cultured overnight at 37°C in LB medium containing 100 μg / mL ampicillin, then transferred at a 1:100 (v / v) ratio to fresh LB medium containing 100 μg / mL ampicillin at 37°C. Cells were incubated at 37°C until the OD600 reached approximately 0.9. The temperature was then cooled to 20°C and the cells were incubated overnight with 0.5 mM (final concentration) isopropyl-β-D-thiogalactopyranoside (IPTG). For CagA... N Cells were harvested by centrifugation and resuspended in buffer A (20 mM Tris, pH 8.0, 150 mM NaCl). Cells were then disrupted by sonication, and lysates were removed by centrifugation (12000 × g, 30 min, 4 °C). Cells containing CagA were then... NThe supernatant was applied to a 5 mL Ni column (Cytiva) pre-equilibrated with buffer A. The column was washed sequentially with 4 column volumes of buffer A, 2 column volumes of buffer B (buffer A containing 20 mM imidazole), and 2 column volumes of buffer C (buffer A containing 300 mM imidazole). The eluted protein was dialyzed against buffer D (20 mM Tris, pH 8.0, 50 mM NaCl), followed by ion-exchange chromatography using a 5 mL QTrap anion exchange column (Cytiva) with a linear gradient of 0 M to 1 M NaCl. Further purification was performed using size exclusion chromatography on a Superdex 200 increase 10 / 300GL column (Cytiva) with buffer D. For the D2 domain, cells expressing this domain were resuspended in buffer E (20 mM Tris, pH 8.0, 500 mM NaCl) and then sonicated on ice. After centrifugation (12,000×g, 30 min, 4°C), the supernatant containing the recombinant D2 domain was collected and loaded onto a 5 mL nickel column pre-equilibrated with buffer E. The column was washed sequentially with 2 column volumes of buffer E, then buffer F (buffer E containing 20 mM imidazole), and eluted with buffer G (buffer E containing 300 mM imidazole). The eluted protein was dialyzed against buffer H (20 mM Tris, pH 8.0, 500 mM NaCl), cleaved overnight with thrombin (1:1000), and immobilized metal affinity chromatography was performed again using a nickel column pre-equilibrated with buffer E. The CagAD2 domain was eluted from a nickel column with buffer F and buffer I (20 mM Tris pH 8.0, 1 M NaCl), followed by size exclusion chromatography using a Superdex 200 increase10 / 300GL column equilibrated with buffer J (20 mM sodium phosphate buffer pH 8.0, 0.2 mM EDTA, 50 mM NaCl).

[0252] Preparation of amyloid-forming proteins and peptides

[0253] Functional amyloid-forming proteins: Expression and purification of CsgA and FapC according to established protocols. 52In short, full-length FapC (amino acids 25-250) from *Pseudomonas* species UK4 and CsgA (amino acids 21-151) from *Escherichia coli* were generated in BL21(DE3) *E. coli* cells using pET28d and pET11d vectors, respectively. Single colonies were inoculated into 50 mL of liquid culture and allowed to grow overnight. The culture was then diluted 40-fold to bring the initial OD600 of the master culture to 0.1. When the OD600 reached 0.6 to 0.8, 0.5 mM or 1 mM IPTG was used for CsgA and FapC, respectively, to initiate protein production. After 12 hours of culture for CsgA and 4 hours for FapC, cells were collected and centrifuged (6000 g, 10 min, 4 °C). Cell lysis was performed in 50 mM Tris containing 8 M guanidine hydrochloride at pH 7.5. The clarified lysates were then processed using a His-Tag affinity column. For effective elution, proteins were released using two imidazole gradients (300 mM and 500 mM, dissolved in 50 mM Tris pH 7.5). Desalting to 50 mM Tris pH 7.5 was performed using a PD-10 column (GE Healthcare) packed with Sephadex G-25 beads.

[0254] For AD-related proteins or peptides: 42 or 40 amino acid residues of Aβ (Aβ42 or Aβ40) and NT * FlSp Soluble tag fusion was performed and expressed in BL21(DE3) Escherichia coli strain. In short, the protocol was followed as previously described. 53 Purification of NT using Ni-NTA column * FlSp -Aβ42 or NT * FlSp -Aβ40. Then use NT. * FlSp -Tev Cut NT * FlSp -Aβ42 or NT * FlSp -Aβ40 fusion protein was prepared and lyophilized. The resulting lyophilized material was dissolved in 20 mM Tris (pH 8.0) containing 7 M guanidine chloride. Subsequently, Aβ42 or Aβ40 monomers were separated in 20 mM NaPi (pH 8.0) containing 0.2 mM EDTA using a Superdex 30 26 / 600 column (Cytiva) and then aliquoted into low-adsorption Eppendorf tubes (Axygene). The Aβ monomer concentration was measured using an extinction coefficient of 1424 M. -1 cm -1 Determined at (A280–A300). Recombinant, native, and full-length tau proteins were analyzed according to the established protocol. 54Expression and purification. In short, full-length tau protein was expressed in BL21(DE3) *E. coli* cells. For purification, the cell pellet was thawed, resuspended, and homogenized. After centrifugation and heat treatment, the heat-stable tau protein in the supernatant was subjected to cation exchange chromatography. The tau protein was then eluted with a NaCl gradient, and the tau-containing fractions were identified by SDS-PAGE. These fractions were combined, desalted, and the tau protein concentration was determined. Finally, the tau protein was aliquoted, frozen, and lyophilized for long-term storage.

[0255] Regarding PD-related proteins: According to previously published reports 55 Recombinant wild-type α-synuclein monomers were prepared. Briefly, α-synuclein was expressed in BL21(DE3) *E. coli* cells. The induced bacterial culture was precipitated and sonicated to lyse the cells. After centrifugation, the supernatant was purified by anion exchange chromatography (HiPrep 16 / 10 Q FF, Cytiva), followed by reversed-phase HPLC (Jupiter 300 C4, 20 mm inner diameter × 250 mm, 10 μm average bead diameter, Phenomenex) and lyophilized. The α-synuclein powder was dissolved in Tris pH 7.5 and the α-synuclein monomers were separated using a Superdex 200 26 / 600 column (Cytiva).

[0256] For T2D-related peptides: IAPP peptide was expressed in BL21(DE3) E. coli cells and purified according to a previous protocol. 56 In short, the cell pellet was resuspended in a solution of 8 M urea and 20 mM Tris at pH 8.0, and then sonicated until the mixture became clear. The resulting lysate was filtered through a 0.22 μm filter to remove any insoluble substances and then loaded onto a HisPrep FF 16 / 10 column (Cytiva, Sweden). The column was washed with a solution containing 15 mM imidazole, 8 M urea, and 20 mM Tris at pH 8.0, and proteins were eluted with a solution of 200 mM imidazole, 8 M urea, and 20 mM Tris at pH 8.0. The eluted NT* FlSp The MetIAPP protein was then dialyzed against 20 mM Tris at pH 8.0. For cleavage, NT* was... FlSpMetIAPP was treated with 100 mM CNBr at pH 1.0 by adding 2 M HCl until the final HCl concentration reached 0.1 M, and incubated overnight at room temperature. The IAPP precipitate was then dissolved in 6 M guanidine hydrochloride and loaded onto a 3 mL Resource RPC column (Cytiva) pre-equilibrated with 0.1% trifluoroacetic acid (TFA) and 2% acetonitrile. The IAPP peptide was eluted with a linear gradient of 2% to 80% acetonitrile, resulting in a single peak. The peak fractions were collected, combined, lyophilized, and redissolved in hexafluoroisopropanol (HFIP) to a concentration of 100 μM, and stored at -20 °C for later use.

[0257] Circular dichroism (CD) spectrum

[0258] CD spectra were acquired at 25°C using a J-1500 CD spectrophotometer (JASCO) equipped with a PTC-517 Peltier thermostatic sample cell holder. (CagA) N Samples were prepared at a concentration of 5 µM in buffer D, while the CagA D2 domain sample was diluted in buffer J. Measurements were performed using quartz glass cuvettes with a path length of 1 mm. Each sample was scanned five times consecutively in the wavelength range of 180 nm to 260 nm, with a step size of 0.5 nm. The average spectrum was obtained after blank subtraction and converted to the mean residue ellipticity (MRE, deg•cm). 2 / dmol).

[0259] Measuring biofilm formation using crystal violet

[0260] Single colonies of *Pseudomonas* species UK4 (WT and pFap) were transferred to 50 ml tubes containing 30 ml LB medium and ampicillin (100 µM) and incubated overnight at 28 °C and 180 RPM. The solutions were then diluted to OD using ampicillin (100 µM). 600 ~0.5, then add 270 µl of it to each well of a 96-well plate (Thermo Fisher Scientific 236105). Insert the nail caps (Nunc-Tsp, Thermo Fisher Scientific 445497) into the wells for 1 hour to initiate biofilm growth on the nail caps, then transfer to a new 96-well plate containing 270 µl of fresh LB medium and 0.03 µM, 0.3 µM, 3 µM, or 6 µM CagA. NThe plates were then incubated at 28°C for 48 hours to initiate growth on the nail caps. After incubation, the nail caps were washed with milliQ water and dried at room temperature for 1 hour. The nail caps were then immersed in a new 96-well plate containing 270 μl of Gram's crystal violet solution for 15 minutes, followed by washing twice to remove excess dye. The bound crystal violet was then released from the nail caps by placing them in a new 96-well plate containing 270 μl of 33% v / v acetic acid (glacial acetic acid diluted with milliQ water) at room temperature for 30 minutes. The released crystal violet was then transferred to a new clear-bottom 96-well plate and measured on a Varioskan LUX. The absorbance intensity at 590 nm was used as a measure of the amount of biofilm grown on the nail caps.

[0261] Thioflavin T (ThT) fluorescence assay

[0262] In order to study CagA N The effects of the CagA D2 domain on the formation of Aβ42, Aβ40, tau, α-synuclein, and IAPP fibrils were determined using ThT assays. ThT fluorescence was recorded using a microplate reader equipped with a 440 nm excitation filter and a 480 nm emission filter (FLUOStar Galaxy, BMG Labtech, Offenberg, Germany). For all experiments, aggregation curves were normalized and averaged using 4 to 5 replicates, with data from a single experimental group recorded from the same plate.

[0263] For Aβ42 and Aβ40: 20 µL of solution (20 mmol / L sodium phosphate buffer, pH 8.0, containing 0.2 mM EDTA) was added to each well of a 384-well black polystyrene microplate (transparent base, non-binding surface, Corning Glass 3766, USA). This solution contained 10 µmol / L ThT, 3 µmol / L Aβ42, and different concentrations of CagA. N Or CagA D2 domain (range 0 nmol / L to 100 nmol / L). The microplate was then incubated at 37 °C under static conditions. For monitoring CagA... N The effect on Aβ40 fibrillation was investigated by adding a similar 20 µL solution (20 mmol / L sodium phosphate buffer, pH 7.4, containing 0.2 mM EDTA) to the wells of a 384-well transparent substrate microplate. This solution contained 10 µmol / L ThT, 5 µmol / L Aβ40 monomer, and different concentrations of CagA. N (Range 0 nmol / L to 1.0 nmol / L), and incubate the plate at 37°C.

[0264] For tau: 15 μM monomeric tau protein was prepared in 20 mM sodium phosphate buffer (pH 7.4, containing 0.2 mM EDTA) along with 50 μM ThT, in the absence and presence of 0 nM to 500 nM CagA. N The samples were incubated under the specified conditions. Samples were partitioned into 384-well plates in six replicates, with two glass beads (1 mm in diameter) added. Fluorescence intensity was measured every 10 minutes at 37°C. Orbital oscillations were applied at 300 rpm for 9 minutes between measurements.

[0265] For α-synuclein: In order to detect CagA N To investigate the effect of the CagA D2 domain on α-synuclein fibrillation, 20 µL solutions were prepared containing 10 µmol / L ThT, 30 µmol / L or 15 µmol / L α-synuclein monomers, and different concentrations of CagA. N Or D2 domain (range 0 µmol / L to 3 µmol / L). Incubate the plate with shaking at 37 °C.

[0266] For IAPP: 20 µL of solution (20 mmol / L sodium phosphate buffer, pH 8.0, containing 0.2 mM EDTA) was added to each well of a 384-well black polystyrene microplate (transparent base, non-binding surface, Corning Glass 3766, USA). This solution contained 10 µmol / L ThT, 10 µmol / L IAPP, and different concentrations of CagA. N (Range 0 nmol / L to 100 nmol / L). The microplate was then incubated at 37°C under static conditions.

[0267] Kinetic analysis

[0268] To extract aggregation half-time and Maximum growth rate Different amyloid-producing proteins or peptides were compared in the presence and absence of CagA. N Or, for the D2 structural domain, the aggregation curve is fitted to the S-shaped equation. 32、57 ,

[0269] ,

[0270] Where A is the amplitude and F0 is the base value.

[0271] For global fitting analysis, the aggregation curve of total fibrillary mass concentration M(t) is described by the following integral rate law, where the additional coefficients are functions of λ and κ, as described by Cohen et al. 58 As stated above.

[0272]

[0273] The intermediate coefficients are functions of λ and κ, and n C n and n2 are the reaction orders for primary and secondary nucleation, respectively:

[0274]

[0275] Amyloid-forming peptides or proteins in the presence or absence of CagA N The aggregation curves for the D2 domain were obtained using the AmyloFit 2.0 platform. 59 (https: / / amylofit.com / amylofitmain / fitter / ) performs global fitting using a secondary nucleation-dominated (unseeded) model. The fitting part is constrained, with two fitting parameters maintaining constant values, resulting in only one rate constant (kn, k+, or k2) being the unique fitting parameter. Parameter n C n1 and n2 are the reaction orders for primary and secondary nucleation, respectively, and both are set to 2.

[0276] Flow-induced dispersion analysis (FIDA)

[0277] α-synuclein monomers were labeled with ALC480, and the free dye was removed by a desalting column. For FIDA (Fida 1 platform, Fidabio) analysis, ALC480-labeled α-synuclein monomers were used as indicators, CagA... N As an analyte. Settings: Measurement time 4 min / data point to 6 min / data point, detection Fida 1nm to 480nm detector, tray 1 5°C, capillary 25°C, PC capillary, 400 mbar.

[0278] Surface plasmon resonance (SPR)

[0279] SPR measurements were performed using a BIAcore 3000 instrument (BIAcore AB). Aβ42 monomers, α-synuclein monomers, oligomers, and protofibrils were immobilized on flow cells of different types of sensor chips (Cytiva) via amine coupling. All immobilization procedures were performed using phosphate-buffered saline (20 mM sodium phosphate, 0.2 mM EDTA, pH 8.0) as the run buffer at a flow rate of 20 μL / min, following the manufacturer's instructions. Blank reference surfaces were prepared on flow cell 3 of each sensor chip using the same coupling protocol, without protein injection. Different proteins or peptides were diluted to 2.5 µM concentration in 10 mM sodium acetate buffer at pH 4.5 and immobilized on flow cell 4 of the CM5 sensor chip using the amine coupling immobilization wizard in the BIAcore 3000 control software to achieve an immobilization level of 300 RU. After fixation, the flow cell was stabilized overnight in a detergent-free HEPES buffered saline (10 mM HEPES, 150 mM NaCl, 0.2 mM EDTA, pH 7.5) at a flow rate of 20 µL / min to remove non-specifically bound proteins.

[0280] For combined analysis, the analyte is diluted to different concentrations in HEPES buffer saline, CagA N The concentration range was 0 nmol / L to 100 nmol / L. Samples were injected onto the chip surface in duplicate at 25 °C at a flow rate of 30 µL / min. All experiments used HEPES-buffered saline as the run buffer, and the chip surface was regenerated with 30 mM NaOH. For each analyte concentration, the blank surface response was subtracted from the immobilized surface response. For affinity analysis, CagA was estimated by plotting the maximum binding response. N Steady-state affinity for different amyloid-producing proteins or peptides. The baseline of the sensor plot was adjusted to zero, and buffer spikes were excluded. A global fit was then performed to reflect binding affinity.

[0281] Aβ42 and CagA N co-incubation

[0282] Aβ42 monomers at concentrations of 3 µmol / L or 5 µmol / L were mixed with different concentrations of CagA N(Range 0 µmol / L to 3.0 µmol / L) Mix in 150 µL of 20 mmol / L sodium phosphate buffer (pH 8.0) containing 0.2 mM EDTA. Prepare the mixture on ice and add 90 µL of the sample to the wells of a half-area 384-well black polystyrene microplate. Incubate the microplate at 37 °C for 25 h. Additionally, store 60 µL of fresh sample at -20 °C for further analysis. After the incubation period, collect the supernatant of the incubated sample by centrifugation (13000 rpm, 1 h, 4 °C). The sample is then analyzed by SDS, Native gel electrophoresis, or mass spectrometry.

[0283] Measuring biofilm formation using crystal violet

[0284] Single colonies of *Pseudomonas* species UK4 (WT and pFap) were transferred to 50 ml tubes containing 30 ml LB medium and ampicillin (100 µM) and incubated overnight at 28 °C and 180 RPM. The solutions were then diluted to OD using ampicillin (100 µM). 600 ~0.5, then add 270 µl of it to each well of a 96-well plate (Thermo Fisher Scientific 236105). Insert the nail caps (Nunc-Tsp, Thermo Fisher Scientific 445497) into the wells for 1 hour to initiate biofilm growth on the nail caps, then transfer to a new 96-well plate containing 270 µl of fresh LB medium and 0.03 µM, 0.3 µM, 3 µM, or 6 µM CagA. N The plates were then incubated at 28°C for 48 hours to initiate growth on the nail caps. After incubation, the nail caps were washed with milliQ water and dried at room temperature for 1 hour. The nail caps were then immersed in a new 96-well plate containing 270 μl of Gram's crystal violet solution for 15 minutes, followed by washing twice to remove excess dye. The bound crystal violet was then released from the nail caps by placing them in a new 96-well plate containing 270 μl of 33% v / v acetic acid (glacial acetic acid diluted with milliQ water) at room temperature for 30 minutes. The released crystal violet was then transferred to a new clear-bottom 96-well plate and measured on a Varioskan LUX. The absorbance intensity at 590 nm was used as a measure of the amount of biofilm grown on the nail caps.

[0285] Nuclear magnetic resonance (NMR) spectroscopy

[0286] On a 700MHz Bruker Avance NMR spectrometer equipped with a triple cryogenic probe, the 18 μM α-synuclein sample was recorded in the absence and presence of 18 μM CagA. N 2D time 1H- 15 N HSQC spectra. Spectra were recorded at 281 K in 20 mM NaP at pH 7.4, 0.2 mM EDTA + 20 mM Tris at pH 8, and 50 mM NaCl (9 1 / 9 H2O / D2O). Cross-peak assignments are based on previously published work. 60 Data was processed using Topspin v.4.0.7 software and Poky was used. 61 Data analysis was performed. Residual gene signals with a signal-to-noise ratio > 12 were excluded from the analysis due to their low signal-to-noise ratio.

[0287] References

[0288] 1Raaijmakers, JM & Mazzola, M. Diversity and natural functions ofantibiotics produced by beneficial and plant pathogenic bacteria. Annu. Rev.Phytopathol. 50, 403-424 (2012). https: / / doi.org:10.1146 / annurev-phyto-081211-172908

[0289] 2Adli, M. The CRISPR tool kit for genome editing and beyond. NatCommun 9, 1911 (2018). https: / / doi.org:10.1038 / s41467-018-04252-2

[0290] 3Kreitz, J. et al. Programmable protein delivery with a bacterialcontractile injection system. Nature 616, 357-364 (2023). https: / / doi.org:10.1038 / s41586-023-05870-7

[0291] 4Chiti, F. & Dobson, C. M. Protein Misfolding, Amyloid Formation, andHuman Disease: A Summary of Progress Over the Last Decade. Annu Rev Biochem86, 27-68 (2017). https: / / doi.org:10.1146 / annurev-biochem-061516-045115

[0292] 5Benson, M. D. et al. Amyloid nomenclature 2018: recommendations bythe International Society of Amyloidosis (ISA) nomenclature committee.Amyloid 25, 215-219 (2018). https: / / doi.org:10.1080 / 13506129.2018.1549825

[0293] 6Wang, X. et al. Rational design of functional amyloid fibrillarassemblies. Chem. Soc. Rev. 52, 4603-4631 (2023). https: / / doi.org:10.1039 / d2cs00756h

[0294] 7Falabella, P. et al. Functional amyloids in insect immune response.Insect biochemistry and molecular biology 42, 203-211 (2012). https: / / doi.org:10.1016 / j.ibmb.2011.11.011

[0295] 8Kenney, J. M., Knight, D., Wise, M. J. & Vollrath, F. Amyloidogenicnature of spider silk. European journal of biochemistry / FEBS 269, 4159-4163(2002). https: / / doi.org:10.1046 / j.1432-1033.2002.03112.x

[0296] 9Qi, X. et al. Spider Silk Protein Forms Amyloid-Like Nanofibrilsthrough a Non-Nucleation-Dependent Polymerization Mechanism. Small 19,e2304031 (2023). https: / / doi.org:10.1002 / smll.202304031

[0297] 10Levkovich, S. A., Gazit, E. & Laor Bar-Yosef, D. Two Decades ofStudying Functional Amyloids in Microorganisms. Trends Microbiol. 29, 251-265(2021). https: / / doi.org:10.1016 / j.tim.2020.09.005

[0298] 11Akbey, Ü. & Andreasen, M. Functional amyloids from bacterialbiofilms - structural properties and interaction partners. Chem.Sci. 13,6457-6477 (2022). https: / / doi.org:10.1039 / d2sc00645f

[0299] 12Landreh, M. et al. The formation, function and regulation ofamyloids: insights from structural biology. J. Intern. Med. 280, 164-176(2016). https: / / doi.org:10.1111 / joim.12500

[0300] 13Bravo, D., Hoare, A., Soto, C., Valenzuela, M. A. & Quest, A. F.Helicobacter pylori in human health and disease: Mechanisms for local gastricand systemic effects. World J. Gastroenterol. 24, 3071-3089 (2018). https: / / doi.org:10.3748 / wjg.v24.i28.3071

[0301] 14Franceschi, F., Gasbarrini, A., Polyzos, S. A. & Kountouras, J.Extragastric Diseases and Helicobacter pylori. Helicobacter 20, 40-46 (2015).https: / / doi.org:https: / / doi.org / 10.1111 / hel.12256

[0302] 15Iino, C. & Shimoyama, T. Impact of Helicobacter pylori infection ongut microbiota. World J. Gastroenterol. 27, 6224-6230 (2021). https: / / doi.org:10.3748 / wjg.v27.i37.6224

[0303] 16Mohammadi, S. O., Yadegar, A., Kargar, M., Mirjalali, H. &Kafilzadeh, F. The impact of Helicobacter pylori infection on gut microbiota-endocrine system axis; modulation of metabolic hormone levels and energyhomeostasis. Journal of Diabetes & Metabolic Disorders 19, 1855-1861 (2020).https: / / doi.org:10.1007 / s40200-020-00608-y

[0304] 17Sheh, A. & Fox, J. G. The role of the gastrointestinal microbiomein Helicobacter pylori pathogenesis. Gut Microbes 4, 505-531 (2013). https: / / doi.org:10.4161 / gmic.26205

[0305] 18Zhao, Y. et al. Helicobacter pylori infection alters gastric andtongue coating microbial communities. Helicobacter 24, e12567 (2019).https: / / doi.org:10.1111 / hel.12567

[0306] 19Zeng, J. et al. Host Cell Antimicrobial Responses againstHelicobacter pylori Infection: From Biological Aspects to TherapeuticStrategies. Int. J. Mol. Sci. 23, 10941 (2022). https: / / doi.org:10.3390 / ijms231810941

[0307] 20Jones, T. A., Hernandez, D. Z., Wong, Z. C., Wandler, A. M. &Guillemin, K. The bacterial virulence factor CagA induces microbial dysbiosisthat contributes to excessive epithelial cell proliferation in the Drosophilagut. PLOS Pathogens 13, e1006631 (2017). https: / / doi.org:10.1371 / journal.ppat.1006631

[0308] 21Saleh, P. et al. Efficiency of Helicobacter pylori InfectionTreatment Protocol: Clarithromycin, Amoxicillin and Omeprazole. Arch ClinInfect Dis 8, 14-17 (2012). https: / / doi.org:10.5812 / archcid.14408

[0309] 22Hatakeyama, M. Structure and function of Helicobacter pylori CagA,the first-identified bacterial protein involved in human cancer.Proc.Jpn.Acad.Ser.B Phys.Biol.Sci. 93, 196-219 (2017). https: / / doi.org:10.2183 / pjab.93.013

[0310] 23Kaplan-Türköz, B. et al. Structural insights into Helicobacterpylori oncoprotein CagA interaction with β1 integrin. Proc.Natl.Acad.Sci.U.S. A. 109, 14640-14645 (2012). https: / / doi.org:10.1073 / pnas.1206098109

[0311] 24Pelz, C., Steininger, S., Weiss, C., Coscia, F. & Vogelmann, R. Anovel inhibitory domain of Helicobacter pylori protein CagA reduces CagAeffects on host cell biology. J. Biol. Chem. 286, 8999-9008 (2011). https: / / doi.org:10.1074 / jbc.M110.166504

[0312] 25Moese, S. et al. Identification of a tyrosine-phosphorylated 35 kDacarboxy-terminal fragment (p35CagA) of the Helicobacter pylori CagA proteinin phagocytic cells: processing or breakage? Proteomics 1, 618-629 (2001).https: / / doi.org:10.1002 / 1615-9861(200104)1:4<618::AID-PROT618>3.0.CO;2-C

[0313] 26Hayashi, T. et al. Tertiary structure-function analysis reveals thepathogenic signaling potentiation mechanism of Helicobacter pylori oncogeniceffector CagA. Cell Host Microbe 12, 20-33 (2012). https: / / doi.org:10.1016 / j.chom.2012.05.010

[0314] 27Akbey, Ü. & Andreasen, M. Functional amyloids from bacterialbiofilms – structural properties and interaction partners. Chemical Science13, 6457-6477 (2022). https: / / doi.org:10.1039 / D2SC00645F

[0315] 28Khurana, R. et al.Mechanism of thioflavin T binding to amyloidfibrils.J. Struct.Biol. 151, 229-238 (2005). https: / / doi.org:10.1016 / j.jsb.2005.06.006

[0316] 29Meisl, G., Michaels, T. C. T., Linse, S. & Knowles, T. P. J.Kinetic Analysis of Amyloid Formation. Methods Mol.Biol. 1779, 181-196(2018). https: / / doi.org:10.1007 / 978-1-4939-7816-8_12

[0317] 30Cohen, S. I., Vendruscolo, M., Dobson, C. M. & Knowles, T. P. Frommacroscopic measurements to microscopic mechanisms of protein aggregation. J.Mol.Biol. 421, 160-171 (2012). https: / / doi.org:10.1016 / j.jmb.2012.02.031

[0318] 31Arosio, P. et al. Kinetic analysis reveals the diversity ofmicroscopic mechanisms through which molecular chaperones suppress amyloidformation. Nature Communications 7, 10948 (2016). https: / / doi.org:ARTN1094810.1038 / ncomms10948

[0319] 32Chen, G. et al. Augmentation of Bri2 molecular chaperone activityagainst amyloid-beta reduces neurotoxicity in mouse hippocampus in vitro.Commun Biol 3, 32 (2020). https: / / doi.org:10.1038 / s42003-020-0757-z

[0320] 33Chen, G. et al. Abilities of the BRICHOS domain to preventneurotoxicity and fibril formation are dependent on a highly conserved Aspresidue. RSC Chemical Biology 3, 1342-1358 (2022). https: / / doi.org:10.1039 / d2cb00187j

[0321] 34Pierce, B. G. et al. ZDOCK server: interactive docking predictionof protein-protein complexes and symmetric multimers. Bioinformatics 30,1771-1773 (2014). https: / / doi.org:10.1093 / bioinformatics / btu097

[0322] 35Radolf, J. D., Caimano, M. J., Stevenson, B. & Hu, L. T. Of ticks,mice and men: understanding the dual-host lifestyle of Lyme diseasespirochaetes. Nature Reviews Microbiology 10, 87-99 (2012). https: / / doi.org:10.1038 / nrmicro2714

[0323] 36Lozupone, C. A., Stombaugh, J. I., Gordon, J. I., Jansson, J. K. &Knight, R. Diversity, stability and resilience of the human gut microbiota.Nature 489, 220-230 (2012). https: / / doi.org:10.1038 / nature11550

[0324] 37Hrncir, T. Gut Microbiota Dysbiosis: Triggers, Consequences,Diagnostic and Therapeutic Options. Microorganisms 10, 578 (2022). https: / / doi.org:10.3390 / microorganisms10030578

[0325] 38Doulberis, M. et al. Review: Impact of Helicobacter pylori onAlzheimer's disease: What do we know so far? Helicobacter 23, e12454 (2018).https: / / doi.org:https: / / doi.org / 10.1111 / hel.12454

[0326] 39Shiota, S. et al. The relationship between Helicobacter pyloriinfection and Alzheimer's disease in Japan. J. Neurol. 258, 1460-1463 (2011).https: / / doi.org:10.1007 / s00415-011-5957-5

[0327] 40Hatakeyama, M. Anthropological and clinical implications for thestructural diversity of the Helicobacter pylori CagA oncoprotein. Cancer Sci.102, 36-43 (2011). https: / / doi.org:10.1111 / j.1349-7006.2010.01743.x

[0328] 41Albaret, G. et al. Alzheimer's Disease and Helicobacter pyloriInfection: Inflammation from Stomach to Brain? J. Alzheimers Dis. 73, 801-809(2020). https: / / doi.org:10.3233 / JAD-190496

[0329] 42Vaezi, M. F. et al. CagA-positive strains of Helicobacter pylorimay protect against Barrett's esophagus. Am. J. Gastroenterol. 95, 2206-2211(2000). https: / / doi.org:10.1111 / j.1572-0241.2000.02305.x

[0330] 43Pastore, A., Raimondi, F., Rajendran, L. & Temussi, P. A. Why doesthe Aβ peptide of Alzheimer share structural similarity with antimicrobialpeptides? Commun Biol 3, 135 (2020). https: / / doi.org:10.1038 / s42003-020-0865-9

[0331] 44Sipe, J. D. et al. Amyloid fibril proteins and amyloidosis:chemical identification and clinical classification International Society ofAmyloidosis 2016 Nomenclature Guidelines. Amyloid 23, 209-213 (2016).https: / / doi.org:10.1080 / 13506129.2016.1257986

[0332] 45Balchin, D., Hayer-Hartl, M. & Hartl, F. U. In vivo aspects ofprotein folding and quality control. Science 353, aac4354 (2016). https: / / doi.org:10.1126 / science.aac4354

[0333] 46Hipp, M. S., Kasturi, P. & Hartl, F. U. The proteostasis networkand its decline in ageing. Nat. Rev. Mol. Cell Biol. (2019). https: / / doi.org:10.1038 / s41580-019-0101-y

[0334] 47Boxer, A. L. & Sperling, R. Accelerating Alzheimer’s therapeuticdevelopment: The past and future of clinical trials. Cell 186, 4757-4772(2023). https: / / doi.org:10.1016 / j.cell.2023.09.023

[0335] 48Wentink, A., Nussbaum-Krammer, C. & Bukau, B. Modulation of AmyloidStates by Molecular Chaperones. Cold Spring Harb. Perspect. Biol. 11, a033969(2019). https: / / doi.org:10.1101 / cshperspect.a033969

[0336] 49Leppert, A. et al. A new kid in the folding funnel: Molecularchaperone activities of the BRICHOS domain. Protein Sci 32, e4645 (2023).https: / / doi.org:10.1002 / pro.4645

[0337] 50Chen, G. & Johansson, J. Potential of molecular chaperones fortreating Alzheimer’s disease. Neural Regeneration Research V19 (2024).

[0338] 51Kronqvist, N. et al. Efficient protein production inspired by howspiders make silk. Nat Commun 8, 15504 (2017). https: / / doi.org:10.1038 / ncomms15504

[0339] 52Nagaraj, M. et al. Chaperones mainly suppress primary nucleationduring formation of functional amyloid required for bacterial biofilmformation. Chemical Science 13, 536-553 (2022). https: / / doi.org:10.1039 / D1SC05790A

[0340] 53Zhong, X. et al. Amyloid Fibril Formation of Arctic Amyloid-beta 1-42 Peptide is Efficiently Inhibited by the BRICHOS Domain. ACS Chem. Biol.17, 2201-2211 (2022). https: / / doi.org:10.1021 / acschembio.2c00344

[0341] 54Danis, C. et al. Nuclear Magnetic Resonance Spectroscopy for theIdentification of Multiple Phosphorylations of Intrinsically DisorderedProteins. J Vis Exp (2016). https: / / doi.org:10.3791 / 55001

[0342] 55Kumar, S. T., Donzelli, S., Chiki, A., Syed, M. M. K. & Lashuel, H.A. A simple, versatile and robust centrifugation-based filtration protocolfor the isolation and quantification of alpha-synuclein monomers, oligomersand fibrils: Towards improving experimental reproducibility in alpha-synuclein research. J. Neurochem. 153, 103-119 (2020). https: / / doi.org:10.1111 / jnc.14955

[0343] 56Biverstål, H. et al. Functionalization of amyloid fibrils via theBri2 BRICHOS domain. Sci. Rep. 10, 21765 (2020). https: / / doi.org:10.1038 / s41598-020-78732-1

[0344] 57Chen, G. et al. Bri2 BRICHOS client specificity and chaperoneactivity are governed by assembly state. Nat Commun 8, 2081 (2017). https: / / doi.org:10.1038 / s41467-017-02056-4

[0345] 58Cohen, S. I. A. et al. A molecular chaperone breaks the catalyticcycle that generates toxic Abeta oligomers. Nat. Struct. Mol.Biol. 22, 207-213 (2015). https: / / doi.org:10.1038 / nsmb.2971

[0346] 59Meisl, G. et al. Molecular mechanisms of protein aggregation fromglobal fitting of kinetic models. Nat. Protoc. 11, 252-272 (2016). https: / / doi.org:10.1038 / nprot.2016.010

[0347] 60Eliezer, D., Kutluay, E., Bussell, R., Jr. & Browne, G.Conformational properties of alpha-synuclein in its free and lipid-associatedstates. J. Mol.Biol. 307, 1061-1073 (2001). https: / / doi.org:10.1006 / jmbi.2001.4538

[0348] 61Lee, W., Rahimi, M., Lee, Y. & Chiu, A. POKY: a software suite formultidimensional NMR and 3D structure calculation of biomolecules.Bioinformatics 37, 3041-3042 (2021). https: / / doi.org:10.1093 / bioinformatics / btab180

[0349] sequence list

[0350]

[0351]

Claims

1. Use of an agent for reducing and / or preventing and / or reversing amyloid formation, wherein the agent comprises the N-terminal region of CagA (CagA N CagA, or a portion thereof or a variant thereof, wherein the N-terminal region of CagA, or a portion thereof or a variant thereof, is capable of reducing and / or preventing and / or reversing amyloid formation.

2. The use according to claim 1, wherein CagA has the sequence of amino acids 1-1186 from Helicobacter pylori strain 26695 or its orthologs, optionally wherein CagA has the amino acid sequence of SEQ ID: NO:

1.

3. The use according to claim 1 or 2, wherein the N-terminal region of the CagA (CagA N ) has the sequence of amino acids 1-884 of CagA from Helicobacter pylori strain 26695 or its orthologs, optionally wherein CagA N It has the amino acid sequence of SEQ ID NO:

2.

4. The use according to any of the preceding claims, wherein the CagA N The length of some or variants ranges from 20 to 400 amino acids.

5. The use according to any of the preceding claims, wherein the CagA N The variants of SEQ ID NO: 2 have at least 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity.

6. The use according to any of the preceding claims, wherein the CagA N The part contains or is composed of the CagA domain II (D2).

7. The use according to any of the preceding claims, wherein the CagA N The portion contains or is composed of the amino acid sequence of SEQ ID NO:

3.

8. The use according to any of the preceding claims, wherein the pharmaceutical agent comprises or is composed of the amino acid sequence of SEQ ID NO:

2.

9. The use according to any of the preceding claims, wherein the ability of said agent to reduce and / or prevent and / or reverse amyloid formation is determined using a thioflavin T (ThT) fluorescence assay, optionally using a ThT assay as described in the appended examples.

10. The use according to any of the preceding claims, wherein the amyloid substance is formed of amyloid fibrils and / or amyloid inclusion bodies; preferably selected from those listed in Tables 1 and 2.

11. The use according to claim 10, wherein the amyloid substance is formed from microbial amyloid fibrillary protein and / or amyloid inclusion bodies, the microbial amyloid fibrillary protein and / or amyloid inclusion bodies being selected from the group comprising: curli protein; CsgA protein; FapC protein, TasA protein, biofilm-associated protein (Bap); PSM; SuhB; CdrA; CsgA; P1; WapA; SMU_63C; microbesin E492; RbmA; TasA; MTP; Tu elongation factor; HpaG; BE-AM1; Rodlins; Chaplins; Het-s; HET-s-like protein; Sup35; Ure2; HIV-1 Tat protein; hepatitis C virus (HCV) core protein; influenza A virus (IAV) matrix protein M1; and polyomavirus capsid protein.

12. Use of an agent for reducing and / or preventing and / or reversing microbial biofilm formation, wherein said agent comprises the N-terminal region of CagA (CagA N CagA, or a portion thereof or a variant thereof, wherein the N-terminal region of CagA, or a portion thereof or a variant thereof, is capable of reducing and / or preventing and / or reversing amyloid formation.

13. A method for reducing and / or preventing and / or reversing microbial biofilm formation, the method comprising subjecting a biofilm or a surface prone to biofilm formation to an N-terminal region containing CagA (CagA N The steps of contacting the agent with CagA or a portion or variant thereof, wherein the N-terminal region of CagA or a portion or variant thereof is capable of reducing and / or preventing and / or reversing amyloid formation.

14. An N-terminal region containing CagA (CagA N A pharmaceutical preparation of CagA or a portion thereof or a variant thereof, wherein the N-terminal region of CagA or a portion thereof or a variant thereof is capable of reducing and / or preventing and / or reversing amyloid formation, for medical use.

15. An N-terminal region containing CagA (CagA N A pharmaceutical agent comprising a portion or variant thereof, wherein the N-terminal region of said CagA or a portion or variant thereof is capable of reducing and / or preventing and / or reversing amyloid formation, for the prevention and / or treatment of diseases or conditions characterized by amyloid formation.

16. An N-terminal region containing CagA (CagA N The use of an agent of CagA or a portion thereof or a variant thereof in the preparation of a medicament for the prevention and / or treatment of a disease or condition characterized by amyloid formation, wherein the N-terminal region of CagA or a portion thereof or a variant thereof is capable of reducing and / or preventing and / or reversing amyloid formation.

17. A method for preventing and / or treating a disease or condition characterized by amyloid formation in a subject, the method comprising administering to the subject an effective amount of an N-terminal region containing CagA (CagA N A pharmaceutical agent comprising a portion or variant thereof, wherein the N-terminal region of CagA or a portion or variant thereof is capable of reducing and / or preventing and / or reversing amyloid formation.

18. The pharmaceutical agent for use according to claim 15, or the use according to claim 16, or the method according to claim 17, wherein the disease or condition characterized by amyloid formation is a protein misfolding disease or a microbial infection that produces a biofilm.

19. The pharmaceutical agent, use, or method of use according to claim 18, wherein the protein misfolding disease is mediated by any of the amyloid fibrils and / or intracellular protein inclusions listed in Tables 1 and 2.

20. A combination of a pharmaceutical agent and an antimicrobial agent according to any one of the preceding claims.

21. A pharmaceutical composition comprising the pharmaceutical agent as described in any one of the preceding claims, and a pharmaceutically acceptable carrier, diluent, and / or excipient.

22. A combination of the pharmaceutical agent according to any one of the preceding claims with other therapeutic components.

23. A pharmaceutical agent, pharmaceutical composition, use or method thereof, substantially as described in the appended description, claims and examples.

Citation Information

Patent Citations

  • Dump truck

    US1618629A

  • Keyboard having a stretchable sinuous contacting member

    US3196219A

  • Drug-delivery device with stretched, rate-controlling membrane

    US3710795A

  • Steroidal aerosol compositions and process for the preparation thereof

    US4044126A

  • Carbonate diester solutions of PGE-type compounds

    US4328245A